Table of Contents

 

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

 Quarterly Report Pursuant to Section 13 or 15(d) of the SecuritySecurities Exchange Act of 1934 for the quarterly period ended February 28,November 30, 2021
   
OR
   
 Transmission Report Pursuant to Section 13 or 15(d) of the SecuritySecurities Exchange Act of 19371934 for the transition period from ______ to ______

 

Commission file number: 001-32046

  

Simulations Plus, Inc.Inc.

(Name of registrant as specified in its charter)

 

California95-4595609
(State or other jurisdiction of Incorporation or Organization)(I.R.S. Employer identification No.)

 

42505 10th Street West

Lancaster, CA 93534-7059

(Address of principal executive offices including zip code)

 

(661(661)) 723-7723

(Registrant’s telephone number, including area code)

 

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:

Title of Each Class

Common Stock, par value $0.001 per share

Trading Symbol

SLP

Name of Each Exchange on Which Registered

NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filingsfiling requirements for the past 90 days.     Yes ☒     No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒     No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a nonacceleratednon-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one):

 

☐   ☒   Large accelerated filerFiler☐   Accelerated filerFiler
☒  ☐   Non-accelerated Filer   Smaller reporting company
   Emerging Growth Company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐   No

 

The number of shares outstanding of the registrant’s common stock, par value $0.001 per share, as of April 12, 2021January 4, 2022, was 20,107,89520,175,426; no shares of preferred stock were outstanding.

.

 

   

 

 

Simulations Plus, Inc.

FORM 10-Q

For the Quarterly Period Ended February 28,November 30, 2021

 

Table of Contents

 

PART I. FINANCIAL INFORMATION
  Page
Item 1.Condensed Consolidated Financial Statements 
   
 Condensed Consolidated Balance Sheets at February 28,November 30, 2021 and August 31, 202020213
   
 Condensed Consolidated Statements of Operations and Comprehensive Income for the three and six months ended February 28,November 30, 2021 and February 29,November 30, 20204
   
 Condensed Consolidated Statements of Shareholders’ Equity for the three and six months ended February 28,November 30, 2021 and February 29,November 30, 20205
   
 Condensed Consolidated Statements of Cash Flows for the sixthree months ended February 28,November 30, 2021 and February 29,November 30, 20206
   
 Notes to Condensed Consolidated Financial Statements7
   
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations2624
   
Item 3.Quantitative and Qualitative Disclosures about Market Risk3730
   
Item 4.Controls and Procedures3730
   
PART II. OTHER INFORMATION
   
Item 1.Legal Proceedings3831
   
Item 1A.Risk Factors3831
   
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds3831
   
Item 3.Defaults upon Senior Securities3831
   
Item 4.Mine Safety Disclosures3831
   
Item 5.Other Information3831
   
Item 6.Exhibits3832
   
 Signatures3933

 

 2 

 

 

Part I. FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements

 

SIMULATIONS PLUS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

             
 (Unaudited) (Audited)  (Unaudited) (Audited) 
 February 28, August 31,  November 30, August 31, 
(in thousands, except share and per share amounts) 2021  2020  2021  2021 
ASSETS             
Current assets             
Cash and cash equivalents $42,385  $49,207  $41,680  $36,984 
Accounts receivable, net of allowance for doubtful accounts of $100 and $50  11,306   7,422 
Revenues in excess of billings  3,837   3,093 
Accounts receivable, net of allowance for doubtful accounts of $12 and $78  11,823   9,851 
Revenue in excess of billings  1,483   3,150 
Prepaid income taxes  1,250   970   584   1,012 
Prepaid expenses and other current assets  1,408   1,596   1,676   1,696 
Short-term investments  75,367   66,804   82,660   86,620 
Total current assets  135,553   129,092   139,906   139,313 
Long-term assets                
Capitalized computer software development costs, net of accumulated amortization of $14,271 and $13,582  6,871   6,087 
Capitalized computer software development costs, net of accumulated amortization of $14,734 and $14,438  8,189   7,646 
Property and equipment, net  924   438   2,339   1,838 
Operating lease right of use assets  1,532   927 
Intellectual property, net of accumulated amortization of $5,801 and $5,087  11,184   11,898 
Other intangible assets, net of accumulated amortization of $1,917 and $1,642  6,733   7,008 
Operating lease right-of-use assets  1,146   1,276 
Intellectual property, net of accumulated amortization of $6,873 and $6,516  10,112   10,469 
Other intangible assets, net of accumulated amortization of $2,319 and $2,186  6,331   6,464 
Goodwill  12,921   12,921   12,921   12,921 
Other assets  51   51   50   51 
Total assets $175,769  $168,422  $180,994  $179,978 
                
LIABILITIES AND SHAREHOLDERS' EQUITY                
Current liabilities                
Accounts payable $400  $351  $19  $387 
Accrued payroll and other expenses  2,891   2,251   3,967   5,604 
Current portion - contracts payable  2,000   2,000 
Billings in excess of revenues  258   141 
Operating lease liability, current portion  469   463 
Contracts payable - current portion  4,671   4,550 
Billings in excess of revenue  52   117 
Operating lease liability - current portion  338   382 
Deferred revenue  523   300   568   534 
Total current liabilities  6,541   5,506   9,615   11,574 
                
Long-term liabilities                
Deferred income taxes, net  2,360   2,354   2,113   1,726 
Operating lease liability  1,064   463   810   896 
Payments due under contracts payable  4,307   4,064 
Total liabilities  14,272   12,387   12,538   14,196 
                
Commitments and contingencies              
                
Shareholders' equity                
Preferred stock, $0.001 par value 10,000,000 shares authorized, 0 shares issued and outstanding  0   0   0   0 
Common stock, $0.001 par value and additional paid in capital —50,000,000 shares authorized, 20,059,528 and 19,923,277 shares issued and outstanding  130,713   128,541 
Common stock, $0.001 par value and additional paid-in capital —50,000,000 shares authorized, 20,168,796 and 20,141,521 shares issued and outstanding  134,512   133,418 
Retained earnings  30,730   27,436   34,224   32,407 
Accumulated other comprehensive income  54   58 
Accumulated other comprehensive loss  (280)  (43)
Total shareholders' equity  161,497   156,035   168,456   165,782 
Total liabilities and shareholders' equity $175,769  $168,422  $180,994  $179,978 

 

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

 

 

 3 

 

 

SIMULATIONS PLUS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

For the three and six months ended February 28, 2021 and February 29, 2020(Unaudited)

 

        
                 Three Months Ended November 30, 
(in thousands, except per common share amounts) Three Months Ended  Six Months Ended  2021  2020 
 (Unaudited) (Unaudited)      
 2021  2020  2021  2020 
Revenues $13,147  $10,350  $23,848  $19,751 
Cost of revenues  2,911   2,666   5,344   5,309 
Gross margin  10,236   7,684   18,504   14,442 
Revenue        
Software $7,362  $6,212 
Services  5,055   4,489 
Total revenue  12,417   10,701 
Cost of revenue        
Software  735   812 
Services  2,021   1,621 
Total cost of revenue  2,756   2,433 
Gross profit  9,661   8,268 
Operating expenses                        
Research and development  882   809 
Selling, general, and administrative  5,458   4,110   9,866   7,623   4,988   4,408 
Research and development  1,292   748   2,101   1,274 
Total operating expenses  6,750   4,858   11,967   8,897   5,870   5,217 
                        
Income from operations  3,486   2,826   6,537   5,545   3,791   3,051 
                        
Other income (expense)                        
Interest income  58   12   119   22   64   61 
Interest expense  (22)  0   (22)  0 
Change in value of contingent consideration  (122)  0   (243)  0 
Income/(Loss) on currency exchange  23   (2)  28   2 
Total other income (expense)  (63)  10   (118)  24 
Change in valuation of contingent consideration  (121)  (121)
Gain on sale of assets  1   0 
Gain on currency exchange  121   5 
Total other income (expense), net  65   (55)
                        
Income before provision for income taxes  3,423   2,836   6,419   5,569 
Income before income taxes  3,856   2,996 
Provision for income taxes  (212)  (686)  (729)  (1,361)  (830)  (517)
Net Income $3,211  $2,150  $5,690  $4,208  $3,026  $2,479 
                        
Earnings per share                        
Basic $0.16  $0.12  $0.28  $0.24  $0.15  $0.12 
Diluted $0.15  $0.12  $0.27  $0.23  $0.15  $0.12 
                        
Weighted-average common shares outstanding                        
Basic  20,006   17,638   19,968   17,624   20,150   19,930 
Diluted  20,842   18,316   20,786   18,306   20,746   20,799 
                        
Other Comprehensive Income (Loss), net of tax                

Other comprehensive income (loss), net of tax

        
Foreign currency translation adjustments  (4)  0   (4)  0   (237)  0 
Comprehensive Income $3,207  $2,150  $5,686  $4,208 
Comprehensive income $2,789  $2,479 

 

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

 

 

 4 

 

 

SIMULATIONS PLUS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

For the three and six months ended February 28, 2021 and February 29, 2020(Unaudited)

 

                        
(in thousands, except per common share amounts) Three Months Ended  Six Months Ended  Three Months Ended November 30, 
 (Unaudited) (Unaudited) 
 2021  2020  2021  2020  2021  2020 
Common stock and additional paid in capital                        
Balance, beginning of period $129,253  $15,830  $128,541  $15,327  $133,418  $128,541 
Exercise of stock options  656   167   836   303   372   180 
Stock-based compensation  717   345   1,166   640   634   449 
Shares issued to Directors for services  87   72   170   144   88   83 
Balance, end of period $130,713  $16,414  $130,713  $16,414  $134,512  $129,253 
                        
Retained earnings                        
Balance, beginning of period $28,720  $23,357  $27,436  $22,355  $32,407  $27,436 
Declaration of dividend  (1,201)  (1,059)  (2,396)  (2,115)  (1,209)  (1,195)
Net income  3,211   2,150   5,690   4,208   3,026   2,479 
Balance, end of period $30,730  $24,448  $30,730  $24,448  $34,224  $28,720 
                        
Accumulated other comprehensive income                
Accumulated other comprehensive income (loss)        
Balance, beginning of period $58  $  $58  $  $(43) $58 
Other comprehensive income (loss)  (4)     (4)   
Other comprehensive loss  (237)   
Balance, end of period $54  $  $54  $  $(280) $58 

Total shareholders’ equity

        156,035      165,782    
Other comprehensive income (loss)                  
Total shareholders’ equity $161,497  $40,862  $161,497  $40,862  $168,456  $158,031 
Common dividends declared per common share $0.06  $0.06  $0.12  $0.12 
Cash dividends declared per common share $0.06  $0.06 

 

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

 

 

 5 

 

 

SIMULATIONS PLUS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

             
 Six Months Ended  Three Months Ended November 30, 
(in thousands) February 28, 2021  February 29, 2020  2021  2020 
Cash flows from operating activities                
Net income $5,690  $4,208  $3,026  $2,479 
Adjustments to reconcile net income to net cash provided by operating activities                
Depreciation and amortization  1,776   1,345   845   865 
Change in value of contingent consideration  243   0   121   121 
Amortization of note premiums  1,276   0 
Amortization of investment premiums  610   630 
Stock-based compensation  1,336   784   722   532 
Deferred income taxes  6   (17)  387   47 
Currency translation adjustments  (4)  0   (237)  0 
(Increase) decrease in                
Accounts receivable  (3,884)  (2,218)  (1,972)  91 
Revenues in excess of billings  (744)  (880)
Revenue in excess of billings  1,667   256 
Prepaid income taxes  (280)  308   428   410 
Prepaid expenses and other assets  188   92   21   (141)
Increase (decrease) in                
Accounts payable  51   421   (368)  (15)
Accrued payroll and other expenses  640   (114)  (1,637)  49 
Billings in excess of revenues  117   93 
Billings in excess of revenue  (65)  65 
Deferred revenue  223   (197)  34   (56)
Net cash provided by operating activities  6,634   3,825   3,582   5,333 
                
Cash flows used in investing activities        
Cash flows provided by (used in) investing activities        
Purchases of property and equipment  (583)  (73)  (561)  (205)
Purchases of short-term investments  (40,789)  0   (12,717)  (30,959)
Proceeds from sale of short-term investments  30,950   0   16,067   6,018 
Capitalized computer software development costs  (1,474)  (1,127)  (838)  (728)
Net cash used in investing activities  (11,896)  (1,200)
Net cash provided by (used in) investing activities  1,951   (25,874)
                
Cash flows used in financing activities                
Payment of dividends  (2,396)  (2,115)  (1,209)  (1,195)
Proceeds from the exercise of stock options  836   303   372   180 
Net cash used in financing activities  (1,560)  (1,812)  (837)  (1,015)
                
Net increase (decrease) in cash and cash equivalents  (6,822)  813   4,696   (21,556)
Cash and cash equivalents, beginning of year  49,207   11,436   36,984   49,207 
Cash and cash equivalents, end of period $42,385  $12,249  $41,680  $27,651 
                
Supplemental disclosures of cash flow information                
Income taxes paid $878  $1,066  $23  $57 
        
Non-Cash Investing and Financing Activities        
Right of use assets capitalized $905  $903 

 

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

 

 

 6 

 

 

SIMULATIONS PLUS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 1: GENERAL

 

This report on Form 10-Q for the quarter ended February 28,November 30, 2021 should be read in conjunction with the our Annual Report on Form 10-K for the year ended August 31, 2020,2021, filed with the Securities and Exchange Commission (“SEC”) on November 16, 2020.October 27, 2021. As contemplated by the SEC under Article 8 of Regulation S-X, the accompanying consolidated financial statements and footnotes have been condensed and therefore do not contain all disclosures required by generally accepted accounting principles. The interim financial data are unaudited; however, in the opinion of Simulations Plus, Inc. ("we", "our", "us"(“we,” “our,” “us”), the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results for the interim periods. Results for interim periods are not necessarily indicative of those to be expected for the full year.

 

Organization

Simulations Plus, Inc. (“Simulations Plus”) was incorporated on July 17, 1996. In September 2014, Simulations Plus acquired all of the outstanding equity interests of Cognigen Corporation (“Cognigen”) and Cognigen became a wholly owned subsidiary of Simulations Plus, Inc. In June 2017, Simulations Plus acquired DILIsym Services, Inc. (“DILIsym”) as a wholly owned subsidiary. In April 2020, Simulations Plus, Inc. acquired Lixoft, a French société par actions simplifiée (“Lixoft”) as a wholly owned subsidiary pursuant to a stock purchase and contribution agreement. (Collectively, “Company”, “we”, “us”,“Company,” “we,” “us,” “our”).  

Effective September 1, 2021, the Company merged Cognigen and DILIsym with and into Simulations Plus, Inc. through short form mergers (the “Mergers”). To effectuate the Mergers, the Company filed Certificates of Ownership with the Secretaries of State of the states of Delaware (Cognigen’s and DILIsym’s state of incorporation) and California (Simulation Plus’ state of incorporation). Consummation of the Mergers was not subject to approval of the Company’s stockholders and did not impact the rights of the Company’s stockholders.

 

Lines of Business

We are a premier developer of drug discovery and development software for modeling and simulation, and for the prediction of molecular properties utilizing artificial intelligence (“AI”) and machine learning based technology. We also provide consulting services ranging from early drug discovery through preclinical and clinical trial data analysis and for submissions to regulatory agencies. Our software and consulting services are provided to major pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, andcompanies. They are also provided to regulatoryacademic agencies worldwide for use in the conduct of industry-based research.research and to regulatory agencies for product approval.

 

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES

 

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Simulations Plus, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation.

 

Use of Estimates

Our financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. Actual results could differ from those estimates. Significant accounting policies for us include revenue recognition, accounting for capitalized computer software development costs, valuation of stock options, and accounting for income taxes.

 

7

Reclassifications

Certain numbers in the prior year have been reclassified to conform to the current year's presentation.

  

Revenue Recognition

We generate revenue primarily from the sale of software licenses and by providing consulting services to the pharmaceutical industry for drug development.

7

 

In accordance with Accounting Standards Codification Topic 606 (ASC Topic 606), “Revenue from Contracts with Customers”, we determine revenue recognition through the following steps:

 

i.Identification of the contract, or contracts, with a customer
ii.Identification of the performance obligations in the contract
iii.Determination of the transaction price
iv.Allocation of the transaction price to the performance obligations in the contract
v.Recognition of revenue when, or as, we satisfy a performance obligation

 

Deferred Commissions

 

Sales commissions earned by our sales force and our commissioned sales representatives are considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions for new contracts are deferred and then amortized on a straight-line basis over a period of benefit. We determineddetermine the period of benefit by taking into consideration our customer contracts, our technology, and other factors. Sales commissions for renewal contracts are deferred and then amortized on a straight-line basis over the related contractual renewal period. Amortization expense is included in sales and marketing expenses on the condensed consolidated statements of operations.

We apply the practical expedient in ASC Topic 606 to expense costs as incurred for sales commissions when the period of benefit would have been one year or less. Most of our contracts are of a duration of one year or less, while few, if any of the longer-term contracts have commissions associated with them.

 

Practical Expedients and Exemptions

 

We have elected the following additional practical expedients in applying Topic 606:

 

·Commission Expense: We apply the practical expedient in ASC Topic 606 to expense costs as incurred for sales commissions when the period of benefit is one year or less. Most of our contracts are of a duration of one year or less; few, if any, of the longer termlonger-term contracts have commissions associated with them.them. This expense is included in the condensed consolidated statements of operations as selling, general, and administrative expense.

 

·

Transaction Price Allocated to Future Performance Obligations: ASC 606 requires that we disclose the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of February 28,November 30, 2021. ASC 606 provides certain practical expedients that limit the requirement to disclose the aggregate amount of transaction price allocated to unsatisfied performance obligations.

 

We applied the practical expedient to not disclose the amount of transaction price allocated to unsatisfied performance obligations when the performance obligation is part of a contract that has an original expected duration of one year or less.

 

Cash and Cash Equivalents

For purposes of the statements of cash flows, we consider all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.

 

8

Accounts Receivable

We analyze the age of customer balances, historical bad-debt experience, customer creditworthiness, and changes in customer payment terms when making estimates of the collectability of our trade accounts receivable balances. If we determine that the financial conditions of any of our customers have deteriorated, whether due to customer-specific or general economic issues, an increase in the allowance may be made. Accounts receivable are written off when allreasonable collection attempts have failed.

 

Investments

 

8

Investments

WeThe Company may invest excess cash balances in short-term and long-term marketable debt securities. Investments may consist of certificates of deposit, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. We accountpaper within the parameters of our Investment Policy and Guidelines. The Company accounts for our investmentits investments in marketable securities in accordance with Financial Accounting Standards Board (FASB)(“FASB”) ASC 320, Investments – Debt and Equity Securities. This statement requires debt securities to be classified into three categories:

 

Held-to-maturity—Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary.

 

Trading Securities—Debt securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings.

 

Available-for-Sale—Debt securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of shareholders’ equity.

 

We classify our investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. During the quarter ended February 28,November 30, 2021, all of our investments were classified as held-to-maturity.

 

Capitalized Computer Software Development Costs

Software development costs are capitalized in accordance with FASB ASC 985-20, Costs of Software to Be Sold, Leased, or Marketed”.Marketed. Capitalization of software development costs begins upon the establishment of technological feasibility and is discontinued when the product is available for sale.

 

The establishment of technological feasibility and the ongoing assessment for recoverability of capitalized software development costs require considerable judgment by management with respect to certain external factors including, but not limited to, technological feasibility, anticipated future gross revenues,revenue, estimated economic life, and changes in software and hardware technologies. Capitalized software development costs are comprised primarily of salaries and direct payroll-related costs and the purchase of existing software to be used in our software products.

 

Amortization of capitalized software development costs is calculated on a product-by-product basis on the straight-line method over the estimated economic life of the products (not to exceed five years). Amortization of software development costs amounted to $365296 thousand and $314325 thousand for the three months ended February 28,November 30, 2021 and February 29, 2020, respectively and $690 thousand and $628 thousand for the six months ended February 28, 2021 and February 29, 2020, respectively. We expect future amortization expense to vary due to increases in capitalized computer software development costs.

 

We test capitalized computer software development costs for recoverability whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

  

9

Property and Equipment

Property and equipment are recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are providedcalculated using the straight-line method over the estimated useful lives as follows:

 

Property and Equipment estimated useful lives 
Equipment5 years
Computer equipment3 to 7 years
Furniture and fixtures5 to 7 years
Leasehold improvementsShorter of life of asset or lease

 

9

Internal-use Software

We have a service contract related to the implementation of internally used software. In accordance with ASC 350-40 “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract”, we have capitalized certain internal-use software which are included in long-term assets.

 

The amortization will be classified as selling, general, and administrative expenses on the condensed consolidated statement of operations, and maintenance and minor upgrades are charged to expense as incurred. Gains and losses on disposals are included in the results of operations. No amortization has been expensed for the project as it is still in progress.

 

Leases

Supplemental balance sheet information related to operating leases was as follows as of February 28,November 30, 2021:

Schedule of lease cost    
(in thousands)    
Right of use assets $1,532 
Lease Liabilities, Current $469 
Lease Liabilities, Long-term $1,064 
Operating lease costs $314 
Weighted Average remaining lease term  3.0 years 
Weighted Average Discount rate  3.79% 
Balance sheet information related to operating leases   
(in thousands)   
Right-of-use assets $1,146 
Lease liabilities, current $338 
Lease liabilities, long-term $810 
Operating lease costs $141 
Weighted average remaining lease term  2.25 years 
Weighted average discount rate  3.79% 

  

Intangible Assets and Goodwill

We perform valuations of assets acquired and liabilities assumed on each acquisition accounted for as a business combination and recognizesrecognize the assets acquired and liabilities assumed at their acquisition-date fair value. Acquired intangible assets include customer relationships, software, trade names, and noncompete agreements. We determine the appropriate useful life by performing an analysis of expected cash flows based on historical experience of the acquired businesses. Intangible assets are amortized over their estimated useful lives using the straight-line method, which approximates the pattern in which the majority of the economic benefits are expected to be consumed.

 

Goodwill represents the excess of the cost of an acquired entity over the fair value of the acquired net assets. Goodwill is not amortized, instead it is tested for impairment annually or when events or circumstances change that would indicate that goodwill might be impaired. Events or circumstances that could trigger an impairment review include, but are not limited to, a significant adverse change in legal factors or in the business climate, an adverse action or assessment by a regulator, unanticipated competition, a loss of key personnel, significant changes in the manner of our use of the acquired assets or the strategy for our overall business, significant negative industry or economic trends, or significant underperformance relative to expected historical or projected future results of operations.

 

10

Goodwill is tested for impairment at the reporting unit level, which is one level below or the same as an operating segment. As of February 28,November 30, 2021, we determined that we have four reporting units: Simulations Plus, Cognigen, DILIsym, and Lixoft. When testing goodwill for impairment, we first perform a qualitative assessment to determine whether it is necessary to perform step one of a two-step annual goodwill impairment test for each reporting unit. weWe are required to perform step one only if it concludes that it is more likely than not that a reporting unit's fair value is less than its carrying value. Should this be the case, the first step of the two-step process is to identify whether a potential impairment exists by comparing the estimated fair values of our reporting units with their respective book values, including goodwill. If the estimated fair value of the reporting unit exceeds book value, goodwill is considered not to be impaired, and no additional steps are necessary. If, however, the fair value of the reporting unit is less than book value, then the second step is performed to determine if goodwill is impaired and to measure the amount of impairment loss, if any. The amount of the impairment loss is the excess of the carrying amount of the goodwill over its implied fair value. The estimate of implied fair value of goodwill is primarily based on an estimate of the discounted cash flows expected to result from that reporting unit but may require valuations of certain internally generated and unrecognized intangible assets such as our software, technology, patents, and trademarks. If the carrying amount of goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to the excess.

 

10

As of February 28,November 30, 2021, the entire balance of goodwill was attributed to three of the our reporting units: Cognigen, DILIsym, and Lixoft. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. We did not0t recognize any impairment charges during the three months and six months ended February 28,November 30, 2021 and February 29, 2020.

 

Reconciliation of Goodwill as of February 28,November 30, 2021:

Schedule of reconciliation of goodwill                         
(in thousands) Cognigen  DILIsym  Lixoft  Total  Cognigen  DILIsym  Lixoft  Total 
Balance, August 31, 2020 $4,789  $5,598  $2,534  $12,921 
Balance, August 31, 2021 $4,789  $5,598  $2,534  $12,921 
Addition  0   0   0   0   0   0   0   0 
Impairments  0   0   0   0   0   0   0   0 
Balance, February 28, 2021 $4,789  $5,598  $2,534  $12,921 
Balance, November 30, 2021 $4,789  $5,598  $2,534  $12,921 

 

Fair Value of Financial Instruments

Assets and liabilities recorded at fair value in the Condensed Balance Sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories, as defined by the standard are as follows:

 

Level Input: Input Definition:
Level I Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.
Level III Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

  

For certain of our financial instruments, including accounts receivable, accounts payable, accrued payroll and other expenses, accrued bonuses to officers, and accrued warranty and service costs, the amounts approximate fair value due to their short maturities.

 

The following table summarizes fair value measurements at February 28, 2021 and August 31, 2020 for assets and liabilities measured at fair value on a recurring basis: 

Schedule of fair value measurements                
February 28, 2021:                
                 
(in thousands) Level 1  Level 2  Level 3  Total 
Cash and cash equivalents $42,385  $0  $0  $42,385 
Short-term investments $75,367  $0  $0   75,367 
Acquisition-related contingent consideration obligations $0  $0  $4,974  $4,974 

August 31, 2020:

(in thousands) Level 1  Level 2  Level 3  Total 
Cash and cash equivalents $49,207  $0  $0  $49,207 
Short-term investments $66,804  $0  $0  $66,804 
Acquisition-related contingent consideration obligations $0  $0  $4,731  $4,731 

 

 

 11 

 

 

As of February 28,The following table summarizes fair value measurements at November 30, 2021 and August 31, 2020,2021 for assets and liabilities measured at fair value on a recurring basis:

November 30, 2021: 

Schedule of fair value measurements                
(in thousands) Level 1  Level 2  Level 3  Total 
Cash and cash equivalents $41,680  $0  $0  $41,680 
Short-term investments $82,364  $0  $0  $82,364 
Acquisition-related contingent consideration obligations $0  $0  $3,338  $3,338 

August 31, 2021:

(in thousands) Level 1  Level 2  Level 3  Total 
Cash and cash equivalents $36,984  $0  $0  $36,984 
Short-term investments $86,484  $0  $0  $86,484 
Acquisition-related contingent consideration obligations $0  $0  $3,217  $3,217 

As of November 30, 2021 and August 31, 2021, we had a liability for contingent consideration related to our acquisition of Lixoft. The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs. The fair value of contingent consideration obligations is based on a discounted cash flow model using a probability-weighted income approach. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period. Changes in the value of the contingent consideration obligations are recorded in our Consolidated Statement of Operations.

 

The following is a reconciliation of contingent consideration value:

Reconciliation of contingent consideration value    
Reconciliation of contingent consideration    
(in thousands)       
Value at August 31, 2020 $4,731 
Value at August 31, 2021 $3,217 
Contingent consideration payments  0   0 
Change in value of contingent consideration  243   121 
Value at February 28, 2021 $4,974 
Value at November 30, 2021 $3,338 

  

Research and Development Costs

Research and development costs are charged to expense as incurred until technological feasibility has been established. These costs include salaries, laboratory experiments, and purchased software that was developed by other companies and incorporated into, or used in the development of, our final products.

 

Income Taxes

We account for income taxes in accordance with ASC 740-10, “Income Taxes” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.

 

Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The provision for income taxes represents the tax payable for the period and the change during the period in deferred tax assets and liabilities.

 

Intellectual property

The following table summarizes intellectual property as of February 28, 2021:       
          
(in thousands) Amortization
Period
 Acquisition
Value
  Accumulated
Amortization
  Net Book
Value
 
Royalty Agreement buy out-Enslein Research Straight line 10 years $75  $67  $8 
Termination/nonassertion agreement-TSRL Inc. Straight line 10 years  6,000   4,075   1,925 
Developed technologies–DILIsym acquisition Straight line 9 years  2,850   1,188   1,662 
Intellectual rights of Entelos Holding Corp. Straight line 10 years  50   12   38 
Developed technologies–Lixoft acquisition Straight line 16 years  8,010   459   7,551 
    $16,985  $5,801  $11,184 

 

 12 

 

 

Intellectual property

The following table summarizes intellectual property as of November 30, 2021: 

Schedule of intellectual property           
(in thousands) Amortization
Period
 Acquisition
Value
  Accumulated
Amortization
  Net Book
Value
 
Royalty Agreement buy out-Enslein Research Straight line 10 years $75  $73  $2 
Termination/nonassertion agreement-TSRL Inc. Straight line 10 years  6,000   4,525   1,475 
Developed technologies–DILIsym acquisition Straight line 9 years  2,850   1,425   1,425 
Intellectual rights of Entelos Holding Corp. Straight line 10 years  50   16   34 
Developed technologies–Lixoft acquisition Straight line 16 years  8,010   834   7,176 
    $16,985  $6,873  $10,112 

The following table summarizes intellectual property as of August 31, 2020:2021:

 

(in thousands) Amortization
Period
 Acquisition
Value
 Accumulated
Amortization
 Net Book
Value
  Amortization
Period
 Acquisition
Value
  Accumulated
Amortization
  Net Book
Value
 
Royalty Agreement buy out-Enslein Research Straight line 10 years $75  $64  $11  Straight line 10 years $75  $71  $4 
Termination/nonassertion agreement-TSRL Inc. Straight line 10 years 6,000 3,775 2,225  Straight line 10 years  6,000   4,375   1,625 
Developed technologies–DILIsym acquisition Straight line 9 years 2,850 1,029 1,821  Straight line 9 years  2,850   1,346   1,504 
Intellectual rights of Entelos Holding Corp. Straight line 10 years 50 10 40  Straight line 10 years  50   15   35 
Developed technologies–Lixoft acquisition Straight line 16 years  8,010  209  7,801  Straight line 16 years  8,010   709   7,301 
   $16,985 $5,087 $11,898    $16,985  $6,516  $10,469 

 

Total amortizationAmortization expense for intellectual property agreements for the three months ended February 28,November 30, 2021 and February 29, 2020 was $357 thousand and $232 thousand, respectively, and total amortization expense for the six months ended February 28, 2021 and February 29, 2020 was $714 thousand and $465357 thousand, respectively.

 

Other intangible assets

Schedule of other intangible assets              
The following table summarizes the Company’s other intangible assets as of February 28, 2021:      
               
(in thousands) Amortization
Period
 Acquisition
Value
  Accumulated
Amortization
  Net Book
Value
 
Cognigen              
   Customer relationships Straight line 8 years $1,100  $894  $206 
   Trade name None  500   0   500 
   Covenants not to compete Straight line 5 years  50   50   0 
DILIsym              
   Customer relationships Straight line 10 years  1,900   713   1,187 
   Trade name None  860   0   860 
   Covenants not to compete Straight line 4 years  80   75   5 
Lixoft              
   Customer relationships Straight line 14 years  2,550   167   2,383 
   Trade name None  1,550   0   1,550 
   Covenants not to compete Straight line 3 years  60   18   42 
    $8,650  $1,917  $6,733 

 

The following table summarizes our other intangible assets as of November 30, 2021:  

Schedule of other intangible assets           
(in thousands) Amortization
Period
 Acquisition
Value
  Accumulated
Amortization
  Net Book
Value
 
Cognigen              
Customer relationships Straight line 8 years $1,100  $997  $103 
Trade name None  500   0   500 
Covenants not to compete Straight line 5 years  50   50   0 
DILIsym              
Customer relationships Straight line 10 years  1,900   855   1,045 
Trade name None  860   0   860 
Covenants not to compete Straight line 4 years  80   80   0 
Lixoft              
Customer relationships Straight line 14 years  2,550   304   2,246 
Trade name None  1,550   0   1,550 
Covenants not to compete Straight line 3 years  60   33   27 
    $8,650  $2,319  $6,331 

 

 

 13 

 

 

The following table summarizes the Company’sour other intangible assets as of August 31, 2020:2021: 

(in thousands) Amortization
Period
 Acquisition
Value
  Accumulated
Amortization
  Net Book
Value
  Amortization
Period
 Acquisition
Value
  Accumulated
Amortization
  Net Book
Value
 
Cognigen                        
Customer relationships Straight line 8 years $1,100  $825  $275  Straight line 8 years $1,100  $963  $137 
Trade name None  500   0   500  None  500   0   500 
Covenants not to compete Straight line 5 years  50   50   0  Straight line 5 years  50   50   0 
DILIsym                        
Customer relationships Straight line 10 years  1,900   618   1,282  Straight line 10 years  1,900   807   1,093 
Trade name None  860   0   860  None  860   0   860 
Covenants not to compete Straight line 4 years  80   65   15  Straight line 4 years  80   80   0 
Lixoft                        
Customer relationships Straight line 14 years  2,550   76   2,474  Straight line 14 years  2,550   258   2,292 
Trade name None  1,550   0   1,550  None  1,550   0   1,550 
Covenants not to compete Straight line 3 years  60   8   52  Straight line 3 years  60   28   32 
   $8,650  $1,642  $7,008    $8,650  $2,186  $6,464 

 

Total amortizationAmortization expense for other intangible assets for the three months ended February 28,November 30, 2021 and February 29, 2020 was $138133 thousand and $87 thousand, respectively, and total amortization expense for the six months ended February 28, 2021 and February 29, 2020 was $275 thousand and $174137 thousand, respectively. According to policy in addition to normal amortization, these assets are tested for impairment as needed.

  

Earnings per Share

We report earnings per share in accordance with FASB ASC 260-10. Basic earnings per share is computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings per share is computed similarsimilarly to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The components of basic and diluted earnings per share for the three and six months ended February 28,November 30, 2021 and February 29, 2020 were as follows:

Schedule of earnings per share                        
 Three months ended November 30, 
(in thousands) Three Months ended  Six Months Ended  2021  2020 
 2021  2020  2021  2020 
Numerator:              
Net income attributable to common shareholders $3,211  $2,150  $5,690  $4,208  $3,026  $2,479 
                        
Denominator:                        
Weighted-average number of common shares outstanding during the period  20,006   17,638   19,968   17,624   20,150   19,930 
Dilutive effect of stock options  836   678   818   682   596   869 
Common stock and common stock equivalents used for diluted earnings per share  20,842   18,316   20,786   18,306   20,746   20,799 

 

 

14

Stock-Based Compensation

Compensation costs related to stock options are determined in accordance with FASB ASC 718-10, “Compensation-Stock Compensation”, using the modified prospective method. Under this method, compensation cost is calculated based on the grant-date fair value estimated in accordance with FASB ASC 718-10, amortized on a straight-line basis over the options’ vesting period. Stock-based compensation expense related to stock options, not including shares issued to Directors for services, was $804634 thousand and $417449 thousand for the three months ended February 28,November 30, 2021 and February 29, 2020, respectively, and $1.3 million and $784 thousand for the six months ended February 28, 2021 and February 29, 2020, respectively. This expense is included in the condensed consolidated statements of operations as Selling,selling, general, and administration and Researchresearch and development expense.

  

14

Impairment of Long-lived Assets

We account for the impairment and disposition of long-lived assets in accordance with ASC 350, “Intangibles – Goodwill and Other” and ASC 360, “Property and Equipment”. Long-lived assets to be held and used are reviewed for events or changes in circumstances that indicate that their carrying value may not be recoverable. We measure recoverability by comparing the carrying amount of an asset to the expected future undiscounted net cash flows generated by the asset. If we determine that the asset may not be recoverable, or if the carrying amount of an asset exceeds its estimated future undiscounted cash flows, we recognize an impairment charge to the extent of the difference between the fair value and the asset's carrying amount. No impairment losses were recorded during the sixthree months ended February 28,November 30, 2021 and February 29, 2020.

 

Recently Issued Accounting Pronouncements

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which is intended to simplify various areas related to the accounting for income taxes and improve consistent application of Topic 740. The guidance eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside-basis differences related to changes in ownership of equity-method investments and foreign subsidiaries. The guidance also simplifies aspects of accounting for franchise taxes and the accounting for the enacted changes in tax laws or rates, as well as the accounting for the step-up in the tax basis of goodwill. ASU 2019-12 is effective for us beginning in fiscal 2022. The adoption of the new standard is not expected to have a material impact on the Company’s consolidated financial statements.

In March 2020, the FASB issued Accounting Standards Update (“ASU”)ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”). The amendments in ASU 2020-04 provide temporary optional expedients and exceptions for applying GAAP to contract modifications, hedging relationships, and other transactions to ease the potential accounting and financial reporting burden associated with transitioning away from reference rates that are expected to be discontinued, including the London Interbank Offered Rate (“LIBOR”). This ASU is effective as of March 12, 2020, through December 31, 2022. The adoption of the new standard has not had and is not expected to have a material impact on our financial statements or related disclosures.

 

In February 2016,October 2021, the FASB issued Accounting Standards Update No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). The amendment requires contract assets and contract liabilities acquired in a business combination to be recognized and measured in accordance with ASC 606, Revenue from Contracts with Customers, as if the acquirer had originated the contract. The Update is intended to improve the accounting for acquired revenue contracts with customers in a business combination, related to the recognition of an acquired contract liability, and to payment terms and their effect on subsequent revenue recognized by the acquirer. The amendment also provides certain practical expedients when applying the guidance. ASU 2021-08 is effective for interim and annual periods beginning after December 15, 2022, on a prospective basis, with early adoption permitted. The Company expects to adopt ASU 2021-08 in the first quarter of fiscal year 2024. The Company is currently evaluating the potential impact of ASU 2021-08 to its consolidated financial statements.

In November 2021, the FASB issued ASU 2016-02, Leases2021-10, “Government Assistance (Topic 842)832), which supersedes existingrequires business entities to disclose information about transactions with a government that are accounted for by applying a grant or contribution model by analogy (for example, IFRS guidance in IAS 20 or guidance on accountingcontributions for leasesnot-for-profit entities in "Leases (Topic 840)"ASC 958-605). For transactions within scope, the new standard requires the disclosure of information about the nature of the transaction, including significant terms and generally requires all leases to be recognized inconditions, as well as the consolidated balance sheet. ASU 2016-02amounts and specific financial statement line items affected by the transaction. The new guidance is effective for annual and interim reporting periods beginning after December 15, 2018. We adopted2021. The Company does not expect that the adoption of this ASUstandard will have a material impact on September 1, 2019.its condensed consolidated financial statements; however, the Company expects to increase its disclosures with respect to government assistance beginning in the first quarter of fiscal year 2023.

15

 

NOTE 3: REVENUE RECOGNITION

  

Contract Liabilities

During the three and six months ended February 28,November 30, 2021 and 2020, we recognized $104353 thousand and $400296 thousand respectively, of revenue that was included in contract liabilities as of August 31, 2021, and 2020, and during the three and six months ended February 29, 2020, we recognized $338 thousand and $773 thousand, respectively, of revenue that was included in contract liabilities as of August 31, 2019.respectively.

 

Disaggregation of RevenuesRevenue

The components of disaggregation of revenue for the three and six months ended February 28,November 30, 2021 and February 29, 2020 were as follows:

Schedule of disaggregation of revenues                
(in thousands) Three Months Ended  Six Months Ended 
  2021  2020  2021  2020 
Software licenses:                
     Point in time $7,536  $5,131  $13,472  $9,494 
     Over time  291   254   503   504 
                 
Consulting services:                
     Over time  5,320   4,965   9,873   9,753 
Total revenue $13,147  $10,350  $23,848  $19,751 

15

Schedule of disaggregation of revenue      
(in thousands) Three Months Ended November 30, 
  2021  2020 
Software licenses:      
Point in time $7,107  $6,001 
Over time  255   211 
         
Consulting services:        
Over time  5,055   4,489 
Total revenue $12,417  $10,701 

 

Remaining Performance Obligations

Remaining performance obligations that do not fall under the expedients require us to perform various consulting and software development services of approximately $3.83.5 million. It is anticipated that a majority of these revenues will be recognized within the next twelve months.

 

NOTE 4: PROPERTY AND EQUIPMENT

 

Property and equipment consisted of the following:

Schedule of property and equipment      
(in thousands) February 28, 2021  August 31, 2020  November 30, 2021  August 31, 2021 
Equipment $1,012  $865  $677  $606 
Computer equipment  583   548   383   293 
Furniture and fixtures  161   161   36   36 
Leasehold improvements  123   114   13   13 
Construction in progress  391   0 
Construction in progress*  1,702   1,302 
Sub total  2,270   1,688   2,811   2,250 
Less: accumulated depreciation  (1,346)  (1,250)  (472)  (412)
Net book value $924  $438  $2,339  $1,838 

*Includes ERP costs associated with the development of internal-use software.

 

NOTE 5: INVESTMENTS

 

We invest a portion of our excess cash balances in short-term debt securities.securities within the parameters of our Investment Policy and Guidelines. Investments at February 28,as of November 30, 2021, consisted of corporate bonds with maturities remaining of less than 12 months. We may also invest excess cash balances in certificates of deposit, money market accounts, government-sponsored enterprise securities, corporate bonds, and/or commercial paper. We account for investments in accordance with FASB ASC 320, Investments – Debt and Equity Securities. At February 28,As of November 30, 2021, all investments were classified as held-to-maturity securities.

The following tables summarize our short-term investments as of February 28, 2021 and August 31, 2020:

Schedule of short term investment                
February 28, 2021 
  
(in thousands) Amortized Cost  

Gross

Unrealized

Gains

  

Gross

Unrealized

Losses

  Fair Value 
                 
Commercial notes (due within one year) $75,367  $0  $(65) $75,302 
Total $75,367  $0  $(65) $75,302 

August 31, 2020

(in thousands) Amortized Cost  

Gross

Unrealized

Gains

  

Gross

Unrealized

Losses

  Fair Value 
                 
Commercial notes (due within one year) $66,804  $0  $(61) $66,743 
Total $66,804  $0  $(61) $66,743 

 

 

 

 16 

 

The following tables summarize our short-term investments as of November 30, 2021 and August 31, 2021:

November 30, 2021

Schedule of short term investments                
(in thousands) Amortized Cost  

Gross

Unrealized

Gains

  

Gross

Unrealized

Losses

  Fair Value 
             
Commercial notes (due within one year) $82,660  $0  $(296) $82,364 
Total $82,660  $0  $(296) $82,364 

August 31, 2021

(in thousands) Amortized Cost  

Gross

Unrealized

Gains

  

Gross

Unrealized

Losses

  Fair Value 
             
Commercial notes (due within one year) $86,620  $0  $(136) $86,484 
Total $86,620  $0  $(136) $86,484 

 

NOTE 6: CONTRACTS PAYABLE

 

DILIsymLixoft Acquisition Liabilities:

On June 1, 2017, we acquired DILIsym. The agreement provided for a working capital adjustment, an eighteen-month $1.0 million holdback provision against certain representations and warranties, and an earnout agreement of up to an additional $5.0 million in earnout payments based on earnings over three years following acquisition. The earnout liability has been recorded at an estimated fair value. Payments under the earnout liability started in fiscal year 2019. In September 2018, $1.6 million was paid out under the first earnout payment, a second earnout payment was made in August 2019 in the amount of $1.7 million. The final payment of $1.8 million was paid in August 2020. In addition, no claims were made against the holdback and the $1.0 million holdback provision was released eighteen months after June 1, 2017.

Lixoft Acquisition Liabilities:

On April 1, 2020, we acquired Lixoft. The agreement provided for a 24 month24-month, $2.0 million holdback escrow provision against certain representations and warrantees, comprised of $1.3 million of cash and shares of stock valued at $667 thousand issued at the date of the agreement. In addition, based on a revenue growthrevenue-growth formula for the two years subsequent to April 1, 2020, the agreement calls for earnout payments of up to $5.5 million (two-thirds cash and one-third newly issued, restrictedunregistered shares of our common stock). The former shareholders of Lixoft can earn up to $2.0 million the first year and $3.5 million in year two. In June 2021, $2.0 million was paid out under the first earnout payment, which was comprised of $1.3 million of cash and $666 thousand worth of common stock.

 

As of February 28,November 30, 2021 and August 31, 20202021, the following liabilities have been recorded:

Schedule of Liabilities      
(in thousands) November 30,
2021
  August 31,
2021
 
Holdback liability $1,333  $1,333 
Earnout liability  3,338   3,217 
Sub total $4,671  $4,550 
Less: current portion  4,671   4,550 
Long-term portion $0  $0 

 

Schedule of Liabilities        
(in thousands) February 28,
2021
  August 31,
2020
 
Holdback liability — Lixoft $1,333  $1,333 
Earnout liability — Lixoft  4,974   4,731 
Sub total $6,307  $6,064 
Less: current portion  2,000   2,000 
Long-term portion $4,307  $4,064 

17

 

NOTE 7: COMMITMENTS AND CONTINGENCIES

 

Leases

We lease approximately 9,255 square feet of office space in Lancaster, California.California, where our corporate headquarters are located. The original lease had a five-year term with two, three-year options to extend. The initial five-year term expired in February 2011, and we extended the lease to February 2, 2014. In June 2013, the lease was amended to extend the term to February 2, 2017. The amended lease also provides for an annual base rent increase of 3% per year and two, two-year options to extend. In May 2016, we exercised the two, two-year options extending the term of the lease through February 2, 2021 at a fixed rate of $25 thousand per month. In December 2020, the lease was amended to extend the termextends to January 31, 2026. The amendment decreased the leased square footage from 13,500 sq. ft to 9,255 sq. ft,2026, and correspondingly reduced the base rent from $25 thousand per month to $16.7is approximately $17 thousand per month. The amended lease also allows usagreement gives the Company the right, upon 180 days’ prior notice, to opt out of all or part of the last 4four years of the lease upon 180-day notice to the landlordterm, with no penalty.

 

17

Our Cognigen subsidiary leasesWe lease approximately 12,6234,317 square feet of office space in Buffalo, New York. The initial five-yearlease term expired in October 2018 and was renewed for a three-year option extending itextends to November 2021. The new30, 2026, and the base rent is approximately $7 thousand per month with an annual 2% increase. The lease agreement provides the Company with two five-year renewal options and the right to terminate the lease with one year’s prior written notice with certain penalties. We previously leased approximately 12,623 square feet of office space at a different location in Buffalo, New York. That lease term extended to November 2021 and the base rent was approximately $16 thousand per month.

 

DILIsym leasesWe lease approximately 2,7003,386 square feet of office space in Research Triangle Park,Durham, North Carolina. The initial three-yearlease term was due to expire October 2020. An amendment to the initial lease became effective April 1, 2020, which added 686 square feet and extended the term of the leaseextends to September 30, 2023. The new2023, and the base rent is approximately $8 thousand per month with an annual 3% adjustment.increase.

 

In Paris, France, Lixoft leasesWe lease approximately 2,300 square feet of office space which as of April 1, 2020, had minimum payments equaling $288 thousand.in Paris, France. The lease is for a 9-year term with an optionextends to terminate every 3 years,November 2024 and expires in November of 2024. Thethe rent is $16approximately $5 thousand per quarter (approximately $5.3 thousand per month)month and can be adjusted each December based on a consumer price index.

 

Rent expense, including common area maintenance fees for the three months ended February 28,November 30 2021, and February 29, 2020 was $147156 thousand and $150185 thousand, respectively, and $332 thousand and $295 thousand for the six months ended February 28, 2021 and February 29, 2020, respectively.

 

Future minimum lease payments under noncancelable operating leases with remaining terms of one year or more at February 28,as of November 30, 2021 were as follows:

 

Future minimum lease payments        
(in thousands)
Years Ending February 28,
   
(in thousands)
Years Ending November 30,
   
2022 $513  $373 
2023  370   357 
2024  328   261 
2025  244   200 
2026  183   33 
Future minimum lease payments  $1,638 
Total undiscounted liabilities  1,224 
Less: imputed interest  (76)
Total future minimum lease payments $1,148 

 

Line of Credit

On March 31, 2020, we entered into a Credit Agreement with Wells Fargo Bank, N.A. The Credit Agreement provides us with a credit facility of $3.5 million through April 15, 2022. As of February 28,November 30, 2021, there were 0 amounts drawn against the line of credit.

 

Employment Agreements

In the normal course of business, we have entered into employment agreements with certain of our key management personnel that may require compensation payments upon termination.

 

License Agreement

We had a royalty agreement with Dassault Systèmes Americas Corp. for access to their Metabolite Database for developing our Metabolite Module within ADMET Predictor™. The module was renamed the Metabolism Module when we released ADMET Predictor version 6 on April 19, 2012. Under this agreement, we paid a royalty of 25% of revenue derived from the sale of the Metabolism/Metabolite module. This agreement was renegotiated, and we do not bear any royalty obligations towards Dassault Systèmes Americas Corp. effective as of June 30, 2019. In addition, the license agreement terminated on September 5, 2020. We have not experienced any adverse impact on revenue since terminating the license agreement.

We are in the process of making arrangements to replace the database, which is expected to be completed by the end of fiscal year 2021.

 

 18 

 

 

Income Taxes

We follow guidance issued by the FASB with regard to our accounting for uncertainty in income taxes recognized in the financial statements. Such guidance prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. Our policy is to include interest and penalties related to income tax expense. We file income tax returns with the IRS and various state jurisdictions as well as with the countries of India and France. Our federal income tax returns for fiscal year 2017 thru 2019years 2018 through 2020 are open for audit, and our state tax returns for fiscal year 2016years 2017 through 20192020 remain open for audit.

 

Our review of prior year tax positions using the criteria and provisions presented in guidance issued by FASB did not result in a material impact on our financial position or results of operations.

 

Legal ProceedingsLitigation

We may be subject to litigation, claims, investigations and audits arising from time to time in the ordinary course of our business; however, at this time, we are not a party to any legal proceedings and are not aware of any pending, threatened, or unasserted legal proceedings of any kind.

   

NOTE 8: SHAREHOLDERS’ EQUITY

 

Shares Outstanding

Shares of common stock outstanding for the quarters ended November 30, 2021 and 2020 were as follows: 

Schedule of common stock outstanding        
  November 30, 
  2021  2020 
Common stock outstanding, beginning of quarter  20,141,521   19,923,277 
Common stock issued during the year  27,275   35,483 
Common stock outstanding, end of quarter  20,168,796   19,958,760 

Dividends

Our Board of Directors declared cash dividends during fiscal years 20212022 and 2020.2021. The details of the dividends paid are in the following tables:

Schedule of dividends declared and paid              
(in thousands, except dividend per share) Fiscal Year 2022       
Record Date Distribution Date Number of Shares
Outstanding on
Record Date
  Dividend per
Share
  Total Amount 
10/25/2021 11/01/2021  20,148  $0.06   1,209 
Total           $1,209 

(in thousands, except dividend per share) Fiscal Year 2021       
Record Date Distribution Date Number of Shares
Outstanding on
Record Date
  Dividend per
Share
  Total Amount 
10/26/2020 11/02/2020  19,924  $0.06  $1,195 
1/25/2021 2/01/2021  20,010  $0.06   1,201 
4/26/2021 5/03/2021  20,115  $0.06   1,207 
7/26/2021 8/02/2021  20,139  $0.06   1,208 
Total           $4,811 

 

Schedule of dividends declared and paid              
(in thousands, except dividend per share amounts)Fiscal Year 2021      
Record Date Distribution Date Number of Shares
Outstanding on
Record Date
  Dividend per
Share
  Total
Amount
 
10/26/2020 11/02/2020  19,924  $0.06  $1,195 
1/25/2021 2/01/2021  20,010  $0.06   1,201 
Total           $2,396 

19

 

(in thousands, except dividend per share amountsFiscal Year 2020      
Record Date Distribution Date Number of Shares
Outstanding on
Record Date
  Dividend per
Share
  Total
Amount
 
10/25/2019 11/01/2019  17,606  $0.06  $1,056 
1/27/2020 2/03/2020  17,646  $0.06   1,059 
4/24/2020 5/01/2020  17,769  $0.06   1,066 
7/27/2020 8/03/2020  17,820  $0.06   1,069 
Total           $4,250 

 

Stock Option Plans

On February 23, 2007, the Company’s Board of Directors adopted, and the shareholders approved, the 2007 Stock Option Plan (the “2007 Plan”), under which a total of 1.0 million shares of common stock were reserved for issuance. On February 25, 2014, the shareholders approved an additional 1.0 million shares, increasing the total number of shares available to be granted under the 2007 Stock Option Plan to 2.0 million. This plan terminated in February 2017 by its term.

 

19

On December 23, 2016, the Company’s Board of Directors adopted, and on February 23, 2017, theits shareholders approved, the Company’s 2017 Equity Incentive Plan (the “2017 Plan”) under which a total of 1.0 million shares of common stock were reserved for issuance. ThisThe plan will terminate in December 20262026. The 2017 Plan was replaced by its term.the Company’s 2021 Plan (as defined below), and as a result, no further issuances of shares may be made under the 2017 Plan.

 

On November 20, 2020,April 9, 2021, the Company’s Board of Directors adopted, an amendment toand on June 23, 2021, its shareholders approved, the 2017Company’s 2021 Equity Incentive Plan to, subject to shareholder approval, increase(the “2021 Plan,” and together with the number of shares reserved for issuance2007 Plan and 2017 Plan, the “Plans”), under the plan from 1.0which 1.3 million shares of common stock were reserved for issuance. The 2021 Plan became effective as of April 9, 2021, and the Company may issue equity awards to 1.75 million shares of common stock.permitted recipients thereunder. The amendment, which was submitted for shareholder approval at our 2021 annual shareholder meeting, was not approved by the shareholders. As a result, we expect to submit a new equity plan for adoption by the Board of Directors and shareholders in May 2021. If approved, the new equity incentive plan will replace the 2017 Equity Incentive Plan, except that outstanding awards granted prior to the adoptionmaximum contractual life of the new equity incentive plan will continue to be governed by the 2017 Equity Incentive Plan.is ten years.

 

As of February 28,November 30, 2021, employees and directors hold Qualified Incentive Stock Options (“ISOs”) and Non-Qualified Stock Options (“NQSOs) to purchase approximately 1.3 million shares of common stock at exercise prices ranging from $6.85 to $61.84.$66.14.

 

The following table summarizes information about stock options: 

Schedule of stock option activity                   

(in thousands, except per share and weighted-average amounts)

Transactions during the six months ended February 28, 2021

 Number of
Options
  Weighted-
Average
Exercise
Price
Per Share
  Weighted-
Average
Remaining
Contractual
Life
 
Outstanding, August 31, 2020  1,224  $17.76   6.79 

(in thousands, except per share and weighted-average amounts)

Transactions during the three months ended November 30, 2021

 Number of
Options
  Weighted-
Average
Exercise
Price
Per Share
  Weighted-
Average
Remaining
Contractual
Life (Years)
 
Outstanding, August 31, 2021  1,184  $25.63   6.47 
Granted  206  $57.83       189  $39.19     
Exercised  (134) $13.11       (28) $16.88     
Cancelled/Forfeited  (34) $26.19       (15) $37.33     
Outstanding, February 28, 2021  1,262  $24.57   6.88 
Exercisable, February 28, 2021  657  $11.68   5.31 
Outstanding, November 30, 2021  1,330  $27.61   6.74 
Exercisable, November 30, 2021  624  $14.47   4.78 

 

The weighted-average remaining contractual life of options outstanding issued under the Plan,Plans, both ISOs and NQSOs, was 6.886.74 years at February 28,November 30, 2021. The total fair value of nonvested stock options as of February 28,November 30, 2021 was $20.18.0 million and is amortizable over a weighted average period of 3.733.54 years.

 

The fair value of these options was estimated at the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option-valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility.

 

20

The following table summarizes the fair value of the options, including both ISOs and NQSOs, granted during the sixthree months ended February 28,November 30, 2021 and fiscal year 2020:2021: 

Schedule of fair value of options        
(in thousands except pricing) Six months ended February 28, 2021  Fiscal Year 2020 
Estimated fair value of awards granted $4,657  $2,997 
Unvested forfeiture rate  0%   0% 
Weighted average grant price $57.83  $39.23 
Weighted average market price $57.83  $39.23 
Weighted average volatility  40.47%   33.56% 
Weighted average risk-free rate  0.60%   1.39% 
Weighted average dividend yield  0.41%   0.65% 
Weighted average expected life  6.64 years   6.67 years 

20

Schedule of fair value of options      
(in thousands except pricing) 

Three Months Ended

November 30, 2021

  Fiscal Year 2021 
Estimated fair value of awards granted $3,029  $5,092 
Unvested forfeiture rate  0%   0% 
Weighted average grant price $39.19  $57.60 
Weighted average market price $39.19  $57.60 
Weighted average volatility  41.89%   40.49% 
Weighted average risk-free rate  1.44%   0.64% 
Weighted average dividend yield  0.62%   0.42% 
Weighted average expected life  6.60 years   6.63 years 

 

The exercise prices for the options outstanding at February 28,November 30, 2021 ranged from $6.85 to $61.84,$66.14, and the information relating to these options is as follows:

(in thousands except prices)

Schedule of options by exercise price range                             
Schedule of options by exercise price rangeSchedule of options by exercise price range           
(in thousands except prices)(in thousands except prices)             
Exercise PriceExercise Price  Awards Outstanding  Awards Exercisable Exercise Price  Awards Outstanding  Awards Exercisable 
LowLow  High  Quantity  Weighted
Average
Remaining
Contractual
Life
  Weighted
Average
Exercise
Price
  Quantity  Weighted
Average
Remaining
Contractual
Life
  Weighted
Average
Exercise
Price
 Low  High  Quantity  Weighted
Average
Remaining
Contractual
Life
  Weighted
Average
Exercise
Price
  Quantity  Weighted
Average
Remaining
Contractual
Life
  Weighted
Average
Exercise
Price
 
$6.85  $8.00   150   3.50 years  $6.85   150   3.50 years  $6.85 6.85  $9.77   310   3.55 years  $8.39   310   3.55 years  $8.39 
$8.01  $16.00   470   5.55 years  $9.93   402   5.48 years  $9.89 9.78  $18.76   227   5.09 years  $10.35   169   5.05 years  $10.43 
$16.01  $24.00   191   7.21 years  $20.47   65   6.41 years  $20.42 18.77  $33.40   280   7.17 years  $25.20   89   6.44 years  $23.64 
$24.01  $38.00   189   8.66 years  $33.45   39   8.63 years  $33.82 33.41  $49.62   258   9.35 years  $38.27   33   7.76 years  $35.44 
$38.01  $52.00   15   9.09 years  $38.59   1   8.98 years  $38.81 49.63  $66.14   255   8.97 years  $58.23   23   8.69 years  $60.98 
$52.01  $61.84   247   9.68 years  $58.53   0     $0 
        1,262   6.88 years  $24.57   657   5.31 years  $11.68         1,330   6.74 years  $27.61   624   4.78 years  $14.47 

 

During the three and six months ended February 28,November 30, 2021 we issued 1,105 and 2,3801,735 shares of stock valued at $87 and $17088 thousand to our nonmanagementnon-management directors as compensation for services rendered to us.

In August 2020, we closed an underwritten public offering of approximately 2.1 million shares of our common stock to the public at $55.00 per share, which included the full exercise of the underwriters’ option to purchase approximately 273 thousand additional shares of common stock. The aggregate gross proceeds to the company from this offering were approximately $115 million before deducting underwriting discounts and commissions. Net proceeds were approximately $107.7 million. The offering was made pursuant to our automatic shelf registration statement on Form S-3 filed with the SEC on July 9, 2020.board-related duties.

 

The balance of par value common stock and additional paid inpaid-in capital as of February 28,November 30, 2021, was $10$10 thousand and $130.7$134.5 million, respectively.

 

NOTE 9: CONCENTRATIONS AND UNCERTAINTIES

 

Financial instruments that potentially subject us to concentration of credit risk consist principally of cash, cash equivalents, trade accounts receivable, and short-term investments. We hold cash and cash equivalents at banks located in California and North Carolina with balances that often exceed FDIC-insured limits. In addition, we hold cash at a bank in France that is not FDIC-insured. Historically, we have not experienced any losses in such accounts. However, considering the current banking environment, we are investigating alternative ways to minimize our exposure to such risks. While we may be exposed to credit losses due to the nonperformance of our counterparties, we do not expect the settlement of these transactions to have a material effect on our results of operations, cash flows, or financial condition. We maintain cash at financial institutions that may, at times, exceed federally insured limits. As of February 28, 2021 we had cash and cash equivalents exceeding insured limits by $12.7 million.

  

Revenue concentration shows that international sales accounted for 34%31% and 33%33% of net sales for the sixthree months ended February 28,November 30, 2021 and February 29, 2020, respectively. TwoFour customers accounted for 13%7%, 5%, 5%, and 5%5% of net sales during the sixthree months ended February 28,November 30, 2021. Three customers accounted for 7%17%, 6%7 (a dealer account in Japan representing various customers)%, and 6%5% of net sales during the sixthree months ended February 29,November 30, 2020.

 

 

 21 

 

 

Accounts receivable concentration shows that fourfive customers each comprised between 15%5, 10%, 6%,% and 5%21 (a dealer account in Japan representing various customers)% of accounts receivable at February 28, 2021. Accountsas of November 30, 2021 compared to five customers each comprising between 6% and 21% of accounts receivable concentration shows that four customers comprised 10% (a dealer account in Japan representing various customers), 5%, 5% and 5% at February 29,as of November 30, 2020.

 

We operate in the computer software industry, which is highly competitive and changes rapidly. Our operating results could be significantly affected by our ability to develop new products and find new distribution channels for new and existing products.

 

The majority of our customers are in the pharmaceutical industry. During economic downturns, we have seen consolidations in the pharmaceutical industry. The extent to which the COVID-19 pandemic impactscontinues to impact our business going forward will depend on numerous factors we cannot reliably predict, including the duration and scope of the pandemic; businesses, and individuals' actions in response to the pandemic; and the impact on economic activity, including the possibility of recession or financial market instability. These factors may adversely impact consumer, business, and government spending as well as customers' ability to pay for our products and services on an ongoing basis.basis. As a result, our growth rate could be affected by consolidation and downsizing in the pharmaceutical industry.

 

NOTE 10: SEGMENT AND GEOGRAPHIC REPORTING

 

We account for segments and geographic revenuesrevenue in accordance with guidance issued by the FASB. Our reportable segments are strategic business units that offer different products and services.

 

Results for each business unit segment and consolidated results are as follows for the three and six months ended February 28,November 30, 2021 and February 29, 2020:2020 were as follows:

 

Schedule of consolidated results from reportable segments                        
(in thousands) Three Months Ended February 28, 2021 
  Simulations Plus  Cognigen  DILIsym  Lixoft*  Eliminations  Total 
Revenues $6,646  $2,783  $2,114  $1,604  $  $13,147 
Income from operations before income taxes $2,121  $279  $260  $826  $  $3,486 
Total assets $165,712  $12,712  $15,242  $21,420  $(39,317) $175,769 
Capital expenditures $232  $126  $5  $15  $  $378 
Capitalized software costs $588  $5  $35  $118  $  $746 
Depreciation and amortization $485  $84  $149  $193  $  $911 
Schedule of consolidated results from reportable segments            
(in thousands) Three Months Ended November 30, 2021 
  Software  Services  Total 
Revenue $7,362  $5,055  $12,417 
Cost of revenue  735   2,021   2,756 
Gross profit $6,627  $3,034  $9,661 
Gross margin  90%   60%   78% 

 

*Lixoft was purchased on April 1, 2020.Our software business and services business represented 59% and 41% of total revenue, respectively, for the three months ended November 30, 2021.

 

(in thousands) Three Months Ended February 29, 2020 
  Simulations Plus  Cognigen  DILIsym  Eliminations  Total 
Revenues $5,904  $2,750  $1,696  $  $10,350 
Income from operations $2,004  $276  $546  $  $2,826 
Total assets $42,881  $10,465  $13,555  $(17,702) $49,199 
Capital expenditures $9  $20  $13  $  $42 
Capitalized software costs $573  $16  $31  $  $620 
Depreciation and amortization $435  $89  $151  $  $675 
(in thousands) Three Months Ended November 30, 2020 
  Software  Services  Total 
Revenue $6,212  $4,489  $10,701 
Cost of revenue  812   1,621   2,433 
Gross profit $5,400  $2,868  $8,268 
Gross margin  87%   64%   77% 

 

Our software business and services business represented 58% and 42% of total revenue, respectively, for the three months ended November 30, 2020. 

Revenue by product and consolidated revenue for the three months ended November 30, 2021 and 2020 were as follows: 

Schedule of geographical revenues                
(in thousands) November 30, 
  2021  2020 
Software revenue                
GastroPlus $3,985   54%  $3,336   54% 
MonolixSuite  1,570   21      1,165   19    
ADMET Predictor  1,459   20      1,172   19    
Other  348   5      539   8    
Total software revenue $7,362   100%  $6,212   100% 
                 
Services revenue                
PKPD $2,326   46%  $2,245   50% 
QSP/QST  1,466   29      1,122   25    
PBPK  859   17      628   14    
Other  404   8      494   11    
Total services revenue $5,055   100%  $4,489   100% 
Total consolidated revenue $12,417      $10,701     

 

 

 22 

 

 

(in thousands) Six Months Ended February 28, 2021 
  Simulations Plus  Cognigen  DILIsym  Lixoft*  Eliminations  Total 
Revenues $12,078  $5,451  $3,486  $2,833  $  $23,848 
Income from operations before income taxes $4,486  $485  $215  $1,351  $  $6,537 
Total assets $165,712  $12,712  $15,242  $21,420  $(39,317) $175,769 
Capital expenditures $371  $189  $5  $18  $  $583 
Capitalized software costs $1,156  $5  $78  $235  $  $1,474 
Depreciation and amortization $936  $165  $298  $377  $  $1,776 

*Lixoft was purchased on April 1, 2020.Revenue by division and consolidated revenue for the three months ended November 30, 2021 and 2020 were as follows:

 

(in thousands) Six Months Ended February 29, 2020 
  Simulations Plus  Cognigen  DILIsym  Eliminations  Total 
Revenues $10,830  $5,137  $3,784  $  $19,751 
Income from operations $3,907  $316  $1,322  $  $5,545 
Total assets $42,881  $10,465  $13,555  $(17,702) $49,199 
Capital expenditures $17  $41  $15  $  $73 
Capitalized software costs $1,030  $36  $61  $  $1,127 
Depreciation and amortization $870  $175  $300  $  $1,345 
(in thousands) November 30, 
  2021  2020 
Simulations Plus $6,515   52%  $5,432   51% 
Cognigen  2,503   20      2,668   25    
DILIsym  1,717   14      1,372   13    
Lixoft  1,682   14      1,229   11    
Total $12,417   100%  $10,701   100% 

 

In addition, we allocate revenuesrevenue to geographic areas based on the locations of our customers. Geographical revenuesRevenue for each geographical area and consolidated revenue for the three and six months ended February 28,November 30, 2021 and February 29, 2020 were as follows:

 

Schedule of geographical revenues                
(in thousands) Three Months Ended February 28, 2021 
  Americas  EMEA  Asia Pacific  Total 
Simulations Plus $2,884  $2,350  $1,412  $6,646 
Cognigen  2,783   0   0   2,783 
DILIsym  2,067   45   2   2,114 
Lixoft  928   676   0   1,604 
Total $8,662  $3,071  $1,414  $13,147 

(in thousands) Three Months Ended February 29, 2020 
  Americas  EMEA  Asia Pacific  Total 
Simulations Plus $2,607  $1,610  $1,687  $5,904 
Cognigen  2,750   0   0   2,750 
DILIsym  1,469   126   101   1,696 
Total $6,826  $1,736  $1,788  $10,350 

23

(in thousands) Six Months Ended February 28, 2021 
  Americas  EMEA  Asia Pacific  Total 
Simulations Plus $5,403  $4,239  $2,436  $12,078 
Cognigen  5,451   0   0   5,451 
DILIsym  3,393   66   27   3,486 
Lixoft  1,538   1,255   40   2,833 
Total $15,785  $5,560  $2,503  $23,848 

(in thousands) Six Months Ended February 29, 2020 
  Americas  EMEA  Asia Pacific  Total 
Simulations Plus $5,153  $2,757  $2,920  $10,830 
Cognigen  5,137   0   0   5,137 
DILIsym  3,207   451   126   3,784 
Total $13,497  $3,208  $3,046  $19,751 
(in thousands) November 30, 
  2021  2020 
Americas $8,459   68%  $7,123   67% 
EMEA  3,025   24      2,478   23    
Asia Pacific  933   8      1,100   10    
Total $12,417   100%  $10,701   100% 

 

NOTE 11: EMPLOYEE BENEFIT PLAN

 

We maintain a 401(k) Plan for all eligible employees, and we make matching contributions equal to 100% of the employee’s elective deferral, not to exceed 4% of total employee compensation. We can also elect to make a profit-sharing contribution. Our contributions to this 401(K) Plan amounted to $131114 thousand and $109121 thousand for the three months ended February 28,November 30, 2021 and February 29, 2020, respectively and $252 thousand and $202 thousand for the six months ended February 28, 2021 and February 29, 2020, respectively.

 

NOTE 12: ACQUISITION

 

On March 31, 2020, we entered into a Stock Purchase and Contribution Agreement (the “Agreement”) with Lixoft.Lixoft, a French société par actions simplifiée (“Lixoft”). On April 1, 2020, we completed the acquisition of all outstanding equity interests of Lixoft pursuant to the terms of the Agreement, with Lixoft becoming our wholly owned subsidiary. We believe the combination of Simulations Plus and Lixoft provides substantial potentialbenefit based on the complementary strengths of each of the companies.

 

Under the terms of the Agreement, as described below, we will pay the former shareholders of Lixoft total consideration of up to $16.5 million, consisting of two-thirds cash and one-third newly issued, unregistered shares of our common stock. In addition, we will pay $3.5 million of excess working capital based on the March 31, 2020 financial statements of Lixoft.

On April 1, 2020, we paid the former shareholders of Lixoft a total of $10.8 million, comprised of cash in the amount of $9.5 million and the issuance of 111,682 shares of our common stock valued at $3.7 million, net of adjustments and a holdback for representations and warranties. Under the terms of the Agreement a price of approximately $32.15 dollars per share was used based upon the volume-weighted average closing price of our shares of common stock for the 30-consecutive-trading-day period ending two trading days prior to April 1, 2020. A total of 9,669 shares are held in an escrow account for potential offset for representations and warrantees. Within three business days following the two-year anniversary of March 31, 2020 (the date of the Agreement) and subject to any offsets for representations and warrantees, we will pay the former shareholders of Lixoft a total of $2.0 million, comprised of $1.3 million of cash and shares released from escrow valued at $666 thousand issued at the date of the Agreement. The Agreement provides for a two-year market standoff period in which the newly issued shares may not be sold by the recipients thereof.

24

In addition, the Agreement calls for earnout payments up to an additional $5.5 million, two-thirds cash and one-third newly issued, unregistered shares of our common stock based on a revenue growth formula each year for the two years subsequent to April 1, 2020. The former shareholders can earn up to $2.0 million the first year and $3.5 million in year two. The earnout liability has been recorded at fair value. In June 2021, under the terms of the Lixoft acquisition agreement, the Company made an earnout payment of $2.0 million (two-thirds cash and one-third newly issued, unregistered shares of common stock) to the former shareholders of Lixoft.

 

UnderFor further details regarding the acquisition method of accounting, the total purchase price reflects Lixoft’s tangibleremaining holdback and intangible assets andearnout liabilities, based on their estimated fair values at the date of the completion of the acquisition (Aprilplease see Note 6, Contracts Payable, to our condensed consolidated financial statements included in Part I, Item 1 2020). The following table summarizes the preliminary allocation of the purchase price for Lixoft:

Allocation of purchase price    
(in thousands)    
Assets acquired, including cash of $3,799 and accounts receivable of $629 $5,007 
Developed technologies acquired  8,010 
Estimated value of intangible assets acquired (customer lists, trade name etc.)  4,160 
Estimated goodwill acquired  2,534 
Liabilities assumed  (1,118)
Total consideration $18,593 

Goodwill was provided in the transaction based on estimates of future earnings of this subsidiary including anticipated synergies associated with the positioning of the combined company as a leader in Model-Based Drug Development.

Consolidated supplemental Pro Forma information

The following unaudited consolidated supplemental pro forma information assumes that the acquisition of Lixoft took placeQuarterly Report on September 1, 2019 for the income statement for the three and six months ended February 28, 2021. These amounts have been calculated after applying our accounting policies and adjusting the results of Lixoft to reflect the same expenses in the three and six months ended February 29, 2020. The adjustments include costs of acquisition, and amortization of intangibles and other technologies acquired during the merger, assuming the fair value adjustments applied on September 1, 2019, together with consequential tax effects.Form 10-Q.

Schedule of Pro Forma Information            
  (Unaudited)  (Unaudited) 
  For the three months ended  For the six months ended 
  (Actual)  (Pro forma)  (Actual)  (Pro forma) 
  February 28, 2021  February 29, 2020  February 28, 2021  February 29, 2020 
Net Sales $13,147  $11,486  $23,848  $22,007 
Net Income $3,211  $2,777  $5,690  $5,293 

 

NOTE 13: SUBSEQUENT EVENTS

 

On Friday, April 9, 2021,Thursday, January 6, 2022, our Board of Directors declared a quarterly cash dividend of $0.06$0.06 per share to our shareholders. The dividend amount of approximately $1.2 million will be distributed on Monday, May 3, 2021,February 7, 2022, for shareholders of record as of Monday, April 26, 2021.

January 31, 2022.

 

 

 2523 

 

 

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

This document and the documents incorporated in this document by reference contain forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical fact contained in this document and the materials accompanying this document are forward-looking statements.

 

The forward-looking statements are based on the beliefs of our management, as well as assumptions made by and information currently available to our management. Frequently, but not always, forward-looking statements are identified by the use of the future tense and by words such as “believes,” expects,” “anticipates,” “intends,” “will,” “may,” “could,” “would,” “projects,” “continues,” “estimates” or similar expressions. Forward-looking statements are not guarantees of future performance and actual results could differ materially from those indicated by the forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by the forward-looking statements.

 

The forward-looking statements contained or incorporated by reference in this document are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”) and are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements include declarations regarding our plans, intentions, beliefs, or current expectations.

 

Among the important factors that could cause actual results to differ materially from those indicated by forward-looking statements are the risks and uncertainties described under “Risk Factors” in our Annual Report on Form 10-K for the year ended August 31, 20202021, filed with the Securities and Exchange Commission (“SEC”) on November 16, 2020October 27, 2021, and elsewhere in this document and in our other filings with the SEC.

 

Forward-looking statements are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document and we do not undertake any obligation to update forward-looking statements to reflect new information, subsequent events, or otherwise.

 

General

 

BUSINESS

 

OVERVIEW

 

Simulations Plus, Inc., incorporated in 1996, is a premier developer of modeling and simulation software for drug discovery and development, including the prediction of properties of molecules utilizing artificial-intelligence-artificial-intelligence and machine-learning-based technology.technologies. We also provide consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions in support of product approval. Our software and consulting services are provided to major pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies andcompanies. They are also provided to academic and regulatory agencies worldwide for use in the conduct of industry-based research. SLPresearch and to regulatory agencies for product approval. The Company is headquartered in Southern California, with additional offices in Buffalo, NY, Research Triangle Park,Durham, NC, and Paris, France. Our common stock tradeshas traded on the Nasdaq Global Select Market under the symbol “SLP” since May 13, 2021, prior to which it traded on the Nasdaq Capital Market under the symbol “SLP”.same symbol. 

We are a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents by providing a wide range of early discovery, preclinical, and clinical consulting services and software. Our innovations in integrating new and existing science in medicinal and computational chemistry, pharmaceutical science, biology, physiology, and machine learning into our software have enabled us to be a leading software provider for physiologically based pharmacokinetics “(PBPK”) modeling and simulation, pharmacometric modeling and simulation, prediction of molecular properties from structure, and prediction of the propensity of drugs to induce liver injury or to treat nonalcoholic fatty liver disease. Our scientific consulting staff draw upon extensive experience across multiple therapeutic areas and a full range of modeling and simulation techniques to assist our clients across the full spectrum of drug development.

26

 

We generate revenue byare a global leader, delivering relevant, cost-effective software and creative and insightful consulting services. Pharmaceutical and biotechnology companies use our software programs and scientific consulting services to guide early drug discovery (molecule design screening and lead optimization), preclinical, and clinical development programs, and development of generic medicines after patent expiration, including using our software products and services to enhance their understanding of the properties of potential new medicines and to use emerging data to improve formulations, select and justify dosing regimens, support the generics industry, optimize clinical trial designs, and simulate outcomes in special populations, such as in elderly and pediatric patients.

 

Simulations Plus acquired

24

Impacts of the COVID-19 Pandemic on our Business

For a discussion of the impacts on, and risks to, our business from COVID-19, please refer to “Our business is subject to risks arising from epidemic diseases, such as the recent outbreak of the COVID-19 illness” included in Item 1A Risk Factors in our Annual Report on Form 10-K for the fiscal year ended August 31, 2021, filed with the SEC on October 27, 2021.

RECENT DEVELOPMENTS

Short-Form Mergers

Effective September 1, 2021, the Company merged Cognigen Corporation (Cognigen) as a whollyand DILIsym, Services, Inc. (wholly owned subsidiary in September 2014. Cognigen was originally incorporated in 1992. Throughsubsidiaries of the integration of CognigenCompany) with and into Simulations Plus, Simulations Plus became a leading providerInc. through short-form mergers (the “Mergers”). To effectuate the Mergers, the Company filed Certificates of population modelingOwnership with the Secretaries of State of the states of Delaware (Cognigen’s and simulation contract research servicesDILIsym’s state of incorporation) and California (the Company’s state of incorporation). Consummation of the Mergers was not subject to approval of the Company’s stockholders and did not impact the rights of the Company’s stockholders.

Summary Results of Operations

Comparison of Three Months Ended November 30, 2021 and 2020:

(in thousands) Three Months Ended November 30, 
  2021  2020  $ Change  % Change 
Revenue $12,417  $10,701  $1,716   16% 
Cost of revenue  2,756   2,433   323   13% 
Gross profit  9,661   8,268   1,393   17% 
Research and development  882   809   73   9% 
Selling, general and administrative  4,988   4,408   580   13% 
Total operating expenses  5,870   5,217   653   13% 
Income from operations  3,791   3,051   740   24% 
Other income (expense), net  65   (55)  120   (218)%
Income before provision for income taxes  3,856   2,996   860   29% 
Provision for income taxes  (830)  (517)  (313)  61% 
Net income $3,026  $2,479  $547   22% 

Revenue

Consolidated revenue increased by approximately $1.7 million or 16% to $12.4 million for the pharmaceuticalthree months ended November 30, 2021, compared to consolidated revenue of approximately $10.7 million for the three months ended November 30, 2020. This increase is primarily due to a $1.2 million or 19% increase in software-related revenue, as well as a $566 thousand or 13% increase in service-related revenue when compared to the three months ended November 30, 2021 and biotechnology industries. Our clinical-pharmacology-based consulting2020.

Cost of Revenue

Consolidated cost of revenue increased by approximately $323 thousand or 13%, to $2.8 million for the three months ended November 30, 2021, compared to approximately $2.4 million for the three months ended November 30, 2020. The increase is primarily due to higher labor-related cost of revenue of $367 thousand, partially offset by a decrease in technical support costs of $40 thousand.

25

Gross Profit

Consolidated gross profit increased by approximately $1.4 million or 17% to $9.7 million for the three months ended November 30, 2021 compared to approximately $8.3 million for the three months ended November 30, 2020. The higher gross profit is primarily due to an increase in gross profit for our software business of approximately $1.2 million, or 23%, and an increase in gross profit for our services include pharmacokineticbusiness of approximately $166 thousand or 6%.

Overall gross margin percentage increased by approximately 1% to 78% for the three months ended November 30, 2021 from 77% for the three months ended November 30, 2020.

Research and pharmacodynamic modeling, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions. We have also developed software for harnessing cloud-based computing in support of modeling and simulation activities and secure data archiving, and we provide consulting services to improve interdisciplinary collaborations andDevelopment Costs

Total research and development productivity.costs increased by $221 thousand for the three months ended November 30, 2021 compared to the three months ended November 30, 2020. During the three months ended November 30, 2021, we incurred approximately $1.7 million of research and development costs; of this amount, $838 thousand was capitalized and $882 thousand was expensed. During the three months ended November 30, 2020, we incurred approximately $1.5 million of research and development costs; of this amount approximately $700 thousand was capitalized and $809 thousand was expensed.

 

Simulation Plus acquired DILIsym Services, Inc. (DILIsym) asSelling, General, and Administrative Expenses

Selling, general, and administrative expenses increased by approximately $580 thousand or 13% to approximately $5.0 million for the three months ended November 30, 2021, from $4.4 million for the three months ended November 30, 2020. The increase was primarily due to higher salary, bonus and other compensation costs of $237 thousand, an increase in payroll taxes of $131 thousand, a wholly owned subsidiary$103 thousand increase in June 2017.insurance costs related to higher liability-related insurance, and a $93 thousand increase in commission costs.

As a percent of revenue, consolidated selling, general, and administrative expenses decreased from 41% to 40% for the same comparative periods.

Other Income/Expense, net

Total other income was $65 thousand for the three months ended November 30, 2021 compared to total other expense of $55 thousand for the three months ended November 30, 2020. The acquisitionvariance of DILIsym positioned us as$120 thousand was primarily due to increases in currency-exchange gains of $116 thousand.

Provision for Income Taxes

Provision for income taxes was $830 thousand for the leading providerthree months ended November 30, 2021 compared to $517 thousand for the same period in the previous year. Our effective tax rate increased 4.2% to 21.5% for the three months ended November 30, 2021 from 17.3% during the same period of Drug Induced Liver Injury (DILI) modelingthe previous year.

Segment Results of Operations by Business Unit

Comparison of Three Months Ended November 30, 2021 and simulation software and related scientific consulting services. In addition2020:

Revenue

(in thousands) Three Months Ended November 30, 
  2021  2020  Change ($)  Change (%) 
Software $7,362  $6,212  $1,150   19% 
Services  5,055   4,489   566   13% 
Total $12,417  $10,701  $1,716   16% 

26

Cost of Revenue

(in thousands) Three Months Ended  November 30, 
  2021  2020  Change ($)  Change (%) 
Software $735  $812  $(77)  (9)%
Services  2,021   1,621   400   25% 
Total $2,756  $2,433  $323   13% 

Gross Profit

(in thousands) Three Months Ended November 30, 
  2021  2020  Change ($)  Change (%) 
Software $6,627  $5,400  $1,227   23% 
Services  3,034   2,868   166   6% 
Total $9,661  $8,268  $1,393   17% 

Software Business

For the three months ended November 30, 2021, the revenue increase of $1.2 million or 19%, compared to the DILIsym® softwarethree months ended November 30, 2020, was primarily due to higher sales from GastroPlus and MonolixSuite of $649 thousand and $405 thousand, respectively. Cost of revenue decreased $77 thousand or 9% during the same periods primarily due to lower technical support costs of $40 thousand and lower amortization costs of $29 thousand. Gross margin increased $1.2 million or 23% during the same periods, primarily due to the increase in revenue.

Services Business

For the three months ended November 30, 2021, the revenue increase of $566 thousand or 13%, compared to the three months ended November 30, 2020, was primarily due to an increase in revenue from QSP/QST consulting services and analytical studies of $436 thousand and $116 thousand, respectively. Cost of revenue increased $400 thousand or 25%, primarily due to an increase in salaries for analysisanalytical studies of potential drug-induced liver injury, DILIsym also has developed a simulation program for analyzing nonalcoholic fatty liver disease (NAFLD) called NAFLDsym™. Both the DILIsym$173 thousand, training costs of $93 thousand, salary contracts of $61 thousand, and NAFLDsym software programs require outputs from PBPK software as inputs. Outputs generated by the GastroPlus™ PBPK software that are required by DILIsym software can be automatically mapped to DILIsym applications; thus, the integrationsubcontractor costs of these technologies provides a seamless capability for analyzing the potential for drug-induced liver injury for new drug compounds and for investigating the potential for new therapeutic agents to treat NAFLD. Since the acquisition, DILIsym has applied its mechanistic modeling resources in other disease areas including idiopathic pulmonary fibrosis (IPF)$57 thousand. Gross margin increased $166 thousand or 6%.

 

Simulations Plus acquired Lixoft as a wholly owned subsidiary on April 1, 2020. Lixoft brings to Simulations Plus its powerful software products, Monolix, SimulxLiquidity and PKanalix, which can take modeling projects from data exploration to clinical trial simulations. In addition, Lixoft provides training and focused consulting services which can accelerate pharmacometric studies. Lixoft’s technologies were developed as a result of a research program led by the French national research institute for digital science and technology (Inria), on nonlinear mixed effect models for advanced population analysis, pharmacometrics, pre-clinical, and clinical trial modeling and simulation. Lixoft continues to work with Inria.Capital Resources

 

PRODUCTS

GeneralAs of November 30, 2021, the Company had $41.7 million in cash and cash equivalents, $82.7 million in short-term investments, and $130.3 million in working capital. Our principal sources of capital have been cash flows from our operations and a public offering in 2020. We have achieved continuous positive operating cash flow over the last twelve fiscal years. 

 

We currently offer eleven software productsbelieve that our existing capital and anticipated funds from operations will be sufficient to meet our anticipated cash needs for pharmaceutical researchworking capital and development: five simulation programs that provide time-dependent results based on solving large setscapital expenditures for the foreseeable future. Thereafter, if cash generated from operations is insufficient to satisfy our capital requirements, we may draw from our revolving line of differential equations: GastroPlus; DDDPlus™; MembranePlus™; DILIsym; and NAFLDsym®; three programs that are based on predicting and analyzing static (not time-dependent) properties of chemicals: ADMET Predictor; MedChem Designer™; and MedChem Studio™ (the combination of ADMET Predictor, MedChem Designer, and MedChem Studio is called our ADMET Design Suite); a program which is designed for rapid clinical trial data analysis and regulatory submissions called PKPlus™; a cloud-based communication and collaboration platform for exploratory data analysis, population PK/PD modeling and reporting called KIWITM; and in April 2020credit with the acquisition of Lixoft,bank, or we addedmay have to sell additional equity or debt securities or obtain expanded credit facilities. In the Monolix Suite of products –event such financing is needed in the future, there can be no assurance that such financing will be available to us, or, if available, that it will be in amounts and on terms acceptable to us. If cash flows from operations became insufficient to continue operations at the current level, and if no additional financing was obtained, then management would restructure the Company in a modeling and simulation solution that allows nonparametric analyses, population PKPD analyses, and modeling and clinical trial simulation.way to preserve its pharmaceutical business while maintaining expenses within operating cash flows.

 

We continue to seek opportunities for strategic acquisitions. If one or more such acquisitions is identified, a substantial portion of our cash reserves may be required to complete it; however, we intend to maintain sufficient cash reserves after any acquisition to provide reasonable assurance that outside financing will not be necessary to continue operations. If we identify an attractive acquisition that would require more cash to complete than we are willing or able to use from our cash reserves, we will consider financing options to complete the acquisition, including obtaining loans and issuing additional securities.

 

 

 27 

 

 

Software businessWe are not aware of any trends or demands, commitments, events or uncertainties that are reasonably likely to result in a decrease in liquidity of our assets. The trend over the last ten years has been increasing cash deposits from our operating cash flows, and we expect that trend to continue for the foreseeable future.

 

Our software business represented 59% of our total revenue during the first six months of fiscal year 2021, and was primarily generated by the following products:

GastroPlus®

Our flagship product, originally introduced in 1998, and currently our largest single source of software revenue, is GastroPlus. GastroPlus mechanistically simulates the absorption, pharmacokinetics, pharmacodynamics, and drug-drug interactions (DDI) of compounds administered to humans and animals and is currently one of the most widely used commercial software of its type by industry, the U.S. Food and Drug Administration (FDA), the U.S. National Institutes of Health (NIH), and other government agencies in the U.S. and around the world. In February 2021, GastroPlus version 9.8.1, which included new mechanisms and updated documentation for key DDI standards models, was released.

ADMET Predictor®

ADMET Predictor is a top-ranked, chemistry-based computer program that takes molecular structures (i.e., drawings of molecules represented in various formats) as inputs and uses artificial intelligence/machine learning technologies to predict approximately 175 different properties for them at an average rate of over 200,000 compounds per hour on a modern laptop computer. This capability allows chemists to generate estimates for a large number of important molecular properties without the need to synthesize and test the molecules, as well as to generate estimates of unknown properties for molecules that have been synthesized, but for which only a limited number of experimental properties have been measured. In September 2020, ADMET Predictor® Version 10.0 (APX), which integrates Artificial Intelligence-driven Drug Design (AIDD) with PBPK, was released.

DILIsym®

The DILIsym software is a quantitative systems pharmacology (“QSP”) program that was introduced in 2011. QSP software models are based on the fundamental understanding of complex biological pathways, disease processes, and drug mechanisms of action, integrating information from experiments and forming hypotheses for the next experimental model. DILIsym deals with the propensity for some drug molecules to induce temporary or permanent changes in biological functions within liver cells (hepatocytes) that can result in damage to the liver (i.e., drug-induced liver injury or DILI).

Monolix Suite

The Monolix Suite is a unique solution for modeling and simulation for pharmaceutical companies, biotechs, and hospitals. It supports nonparametric analyses, population PKPD analyses and modeling, and clinical trial simulation. The extended MonolixSuite contains three main products: Monolix, Simulx, and PKanalix. These products are interconnected and interoperable, i.e., allowing users to go from one application to another one without changing anything in terms of data set or of biological models. Monolix 2020R1 was released in November 2020, which combines the most advanced algorithms with unique ease of use.

Consulting Services

Our consulting business represented 41% of our total revenue during the first six months of fiscal year 2021, and was primarily generated by the following services:

PKPD

Our clinical-pharmacology-based consulting services include population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions. In addition to modeling and simulation consulting services, we provide expertise and assistance with development-related decision making and support for regulatory interactions related to dose selection, clinical trial design, and understanding of the determinants of safety and efficacy for new medicines.

28

QSP/QST

We provide creative and insightful consulting services to support our QSP/QST modeling focused on heart failure, liver safety, and radiation syndrome, as well as other areas. Pharmaceutical and biotechnology companies use our scientific consulting services to guide early drug discovery (molecule design screening and lead optimization), preclinical, and clinical development programs. This includes using our software products and services to enhance their understanding of the properties of potential new medicines and to use emerging data to improve formulations, select and justify dosing regimens, support the generics industry, optimize clinical trial designs, and simulate outcomes in special populations, such as in elderly and pediatric patients.

PBPK

Beginning in 2014, the FDA and other regulatory agencies began to emphasize the need to encourage mechanistic PBPK modeling and simulation in clinical pharmacology, with final guidance documents completed in 2018. New draft guidance documents were released in October 2020 focused on additional applications for biopharmaceuticals. This has resulted in an increased need for us to provide consulting-related services to support this sophisticated technique. We support Model Informed Drug Discovery and Development throughout the entire product lifecycle: from discovery through translation research and clinical development when an organization does not have the time or resources to use our software, directly. More specifically, our clients seek out our consulting services to acquire scientific, therapeutic-area-related modeling and simulation expertise that they do not have in-house.

Summary Results of Operations

Three Months Ended February 28, 2021 compared with Three Months Ended February 29, 2020:

(in thousands) Three Months Ended 
  February 28, 2021  February 29, 2020  $ Change  % Change 
Revenues $13,147  $10,350  $2,797   27%
Cost of revenues  2,911   2,666   245   9 
Gross margin  10,236   7,684   2,552   33 
Selling, general and administrative  5,458   4,110   1,348   33 
Research and development  1,292   748   544   73 
Total operating expenses  6,750   4,858   1,892   39 
Income from operations  3,486   2,826   660   23 
Other income (expense)  (63)  10   (73)  (730)
Income before provision for income taxes  3,423   2,836   587   21 
(Provision for) income taxes  (212)  (686)  474   (69)
Net income $3,211  $2,150  $1,061   49%

Revenues

Consolidated revenues increased by $2.8 million or 27% to $13.1 million for the three months ended February 28, 2021 compared to consolidated revenue of approximately $10.3 million for the three months ended February 29, 2020. This increase is primarily due to a $2.4 million or 45% increase in consolidated software-related revenue, and a $0.4 million or 7% increase in consolidated consulting and analytical study revenues when comparing the three months ended February 28, 2021 and February 29, 2020.

Cost of Revenues

Consolidated cost of revenues increased by $0.2 million, or 9%, to $2.9 million for the three months ended February 28, 2021 compared to $2.7 million for the three months period ended February 29, 2020. The increase is primarily due to a $0.2 million or 9% increase in labor-related contract research organization fees for the DILIsym division.

29

Gross Margin

Consolidated gross margin increased by approximately $2.5 million or 33% to $10.2 million for the three months ended February 28, 2021 compared to $7.7 million for the three months ended February 29, 2020. The higher gross margin is primarily due to the addition of the Lixoft division, which contributed $1.4 million to the increase, as well as the Simulations Plus division’s gross margin increase of $0.8 million or 16%. The gross margin for the Cognigen and DILIsym Divisions both increased by approximately $0.2 million, respectively, for the quarter.

Overall gross margin percentage increased by 4% to 78% for the three months ended February 28, 2021 from 74% for the three months period ended February 29, 2020.

Selling, General and Administrative Expenses

Selling, general, and administrative expenses increased by approximately $1.4 million, or 33% to $5.5 million for the three months period ended February 28, 2021 from $4.1 million for the three months period ended February 29, 2020. As a percent of revenues, Selling, general, and administrative expense increased from 40% to 42% for the same comparative periods.

The increase in Selling, General, and Administrative expense was primarily due to the following:

·Salaries and wages increased by $0.7 million due to higher corporate salaries, bonuses, and severance costs, as well as an increase in headcount and higher contract labor costs;
·Payroll tax expense increased $0.3 million due to higher headcount and wages;
·Insurance expense increased by $0.1 million due to cost increases, higher employee counts and increased liability-related insurance.

Research and Development Costs

Total research and development costs increased by $0.7 million for the three months ended February 28, 2021 compared to the three months ended February 29, 2020. During the second quarter of fiscal year 2021, we incurred approximately $2.0 million of research and development costs; of this amount, $0.7 million was capitalized and $1.3 million was expensed. For the three months ended February 29, 2020, we incurred approximately $1.3 million of research and development costs; of this amount, approximately $0.6 million was capitalized and approximately $0.7 million was expensed.

Other Income (Expense)

Total other expense was $63 thousand for the three months ended February 28, 2021 compared to total other income of $10 thousand for the three months ended February 29, 2020. The variance of $73 thousand is primarily due to a change in the valuation of contingent consideration, partially offset by an increase in interest income resulting from short-term investments.

Provision for Income Taxes

The provision for income taxes was $0.2 million for the three months ended February 28, 2021 compared to $0.7 million for the same period in the previous year. Our effective tax rate decreased 18.0% to 6.2% for the three months ended February 28, 2021 from 24.2% during the same period of the previous year primarily due to the disqualified disposition of options exercised.

30

Six Months Ended February 28, 2021 compared with Six Months Ended February 29, 2020:

(in thousands) Six Months Ended 
  February 28, 2021  February 29, 2020  Change ($)  Change (%) 
Revenues $23,848  $19,751  $4,097   21%
Cost of revenues  5,344   5,309   35   1 
Gross margin  18,504   14,442   4,062   28 
Selling, general and administrative  9,866   7,623   2,243   29 
Research and development  2,101   1,274   827   65 
Total operating expenses  11,967   8,897   3,070   35 
Income from operations  6,537   5,545   992   18 
Other income (expense)  (118)  24   (142)  (592)
Income before provision for income taxes  6,419   5,569   850   15 
Provision for income taxes  (729)  (1,361)  632   (46)
Net income $5,690  $4,208  $1,482   35%

Revenues

Consolidated revenues increased by$4.1 million or 21% to $23.8 million for the six months ended February 28, 2021 compared to approximately $19.7 million for the six months ended February 29, 2020.

This increase is primarily due to a $4.0 million or 40% increase in consolidated software-related revenue when comparing the six months ended February 28, 2021 and February 29, 2020.

Cost of Revenues

Consolidated cost of revenues increased slightly for the six months ended February 28, 2021 compared to the six months ended February 29, 2020. The increase is primarily due to higher amortization of software development costs with the purchase of Lixoft, offset by lower salary contracts for the Cognigen division.

Gross Margin

Consolidated gross margin increased $4.1 million or 28% to $18.5 million for the six months ended February 28, 2021 compared to $14.4 million for the six months ended February 29, 2020.

The higher gross margin is primarily due to the addition of the Lixoft division, which contributed $2.5 million to the increase, as well as the Simulations Plus division’s gross margin increase of $1.4 million or 15%. The Cognigen Division gross margin increased $0.6 million or 22%. This was offset by a decrease for DILIsym Divisions’ gross margin of $0.3 million or 11% for the quarter.

Overall gross margin percentage increased by 5% to 78% for the six months ended February 28, 2021 from 73% for the six months ended February 29, 2020.

Selling, General and Administrative Expenses

Selling, general, and administrative expenses increased $2.2 million, or 29% to $9.9 million for the six months ended February 28, 2021 from approximately $7.7 million for the six months ended February 29, 2020. As a percent of revenues, Selling, general, and administrative expense increased from 39% to 41% for the same comparative periods.

31

The increase in Selling, General, and Administrative expense was primarily due to the following:

·Salaries and wage increased by $1.1 million due to higher corporate salaries, bonuses, and severance costs, as well as an increase in headcount and higher contract labor costs;
·Payroll tax expense increased $0.5 million due to higher headcount and wages;
·Insurance expense increased by $0.2 million due to cost increases, higher employee counts and increased liability-related insurance;
·

Professional fees increased by $0.2 million primarily due to higher accounting costs.

Research and Development Costs

Total research and development costs increased by $1.1 million for the six months ended February 28, 2021 compared to the six months ended February 29, 2020. During the first two quarters of fiscal year 2021, we incurred approximately $3.5 million of research and development costs; of this amount, $1.4 million was capitalized and $2.1 million was expensed. For the six months ended February 29, 2020 we incurred approximately $2.4 million of research and development costs; of this amount, $1.1 million was capitalized and $1.3 million was expensed.

Other Income (Expense)

Total other expense was $118 thousand for the six months ended February 28, 2021 compared to total other income of $24 thousand for the six months ended February 29, 2020. The variance of $142 thousand is primarily due to a change in the valuation of contingent consideration, partially offset by an increase in interest income resulting from short-term investments.

Provision for Income Taxes

The provision for income taxes was $0.7 million for the six months ended February 28, 2021 compared to $1.4 million for the same period in the previous year. Our effective tax rate decreased 13.0% to 11.4% for the six months ended February 28, 2021 from 24.4% during the same period of the previous year primarily due to the disqualified disposition of options exercised.

Segment Results of Operations

Three Months Ended February 28, 2021 compared with Three Months Ended February 29, 2020:

Revenues

(in thousands) Three Months Ended 
  February 28, 2021  February 29, 2020  Change ($)  Change (%) 
Simulations Plus $6,646  $5,904  $742   13%
Cognigen  2,783   2,750   33   1 
DILIsym  2,114   1,696   418   25 
Lixoft*  1,604      1,604   100 
Total $13,147  $10,350  $2,797   27%

32

Cost of Revenues

(in thousands) Three Months Ended 
  February 28, 2021  February 29, 2020  Change ($)  Change (%) 
Simulations Plus $773  $846  $(73)  (9)%
Cognigen  1,224   1,341   (117)  (9)
DILIsym  725   479   246   51 
Lixoft*  189      189   100 
Total $2,911  $2,666  $245   9%

Gross Margin

(in thousands) Three Months Ended 
  February 28, 2021  February 29, 2020  Change ($)  Change (%) 
Simulations Plus $5,873  $5,058  $815   16%
Cognigen  1,559   1,409   150   11 
DILIsym  1,389   1,217   172   14 
Lixoft*  1,415      1,415   100 
Total $10,236  $7,684  $2,552   33%

*Lixoft was acquired on April 1, 2020.

Simulations Plus

For the three months ended February 28, 2021, the revenue increase of $0.7 million or 13%, compared to the three months ended February 29, 2020 was primarily due to higher sales from GastroPlus ($0.5 million) and ADMET Software ($0.2 million). Cost of revenue decreased $0.1 million during the same periods and gross margin increased $0.8 million or 16%, primarily due to the change in revenue.

Cognigen

For the three months ended February 28, 2021, revenue increased marginally compared to the three months ended February 29, 2020. Cost of revenues decreased $0.1 million or 9%, primarily due to a reduction in salaries. Gross margin increased $0.2 million or 11%, primarily due to the decrease in the cost of revenues.

DILIsym

For the three months ended February 28, 2021, the revenue increase of $0.4 million or 25% compared to the three months ended February 29, 2020 was primarily due to higher revenue from DILIsym consulting services of $0.3 million. Cost of revenue increased $0.2 million or 51%, primarily due to an increase in contract research organization fees. Gross margin increased $0.2 million or 14%.

Lixoft

For the three months ended February 28, 2021, the revenue increase of $1.6 million compared to the three months ended February 29, 2020 was primarily due to the purchase of Lixoft on April 1, 2020. Software sales of Monolix Suite generated 97% of total revenue and 3% was generated from consulting services. Cost of revenue and gross margin increases of $0.2 million and $1.4 million, respectively, were both due to the purchase of Lixoft on April 1, 2020.

33

Six Months Ended February 28, 2021 compared with Six Months Ended February 29, 2020:

Revenues

(in thousands) Six Months Ended 
  February 28, 2021  February 29, 2020  Change ($)  Change (%) 
Simulations Plus $12,078  $10,830  $1,248   12%
Cognigen  5,451   5,137   314   6 
DILIsym  3,486   3,784   (298)  (8)
Lixoft*  2,833      2,833   100 
Total $23,848  $19,751  $4,097   21%

Cost of Revenues

(in thousands) Six Months Ended 
  February 28, 2021  February 29, 2020  Change ($)  Change (%) 
Simulations Plus $1,484  $1,591  $(107)  (7)%
Cognigen  2,370   2,611   (241)  (9)
DILIsym  1,110   1,107   3    
Lixoft*  380      380   100 
Total $5,344  $5,309  $35   1%

Gross Margin

(in thousands) Six Months Ended 
  February 28, 2021  February 29, 2020  Change ($)  Change (%) 
Simulations Plus $10,594  $9,239  $1,355   15%
Cognigen  3,081   2,526   555   22 
DILIsym  2,376   2,677   (301)  (11)
Lixoft*  2,453      2,453   100 
Total $18,504  $14,442  $4,062   28%

*Lixoft was acquired on April 1, 2020.

Simulations Plus

For the six months ended February 28, 2021, the revenue increase of $1.2 million or 12% compared to the six months ended February 29, 2020 was primarily due to higher sales from GastroPlus ($0.9 million) and ADMET Software ($0.3 million). Cost of revenue decreased $0.1 million or 7% during the same periods, and gross margin increased $1.4 million or 15%, primarily due to the change in revenue.

34

Cognigen

For the six months ended February 28, 2021, the revenue increase of $0.3 million or 6% compared to the six months ended February 29, 2020 was primarily due to an increase in grant revenue. Cost of revenue decreased $0.2 million or 9%, primarily due to a reduction in salaries during the same periods. Gross margin increased by approximately $0.6 million or 22%.

DILIsym

For the six months ended February 28, 2021, the revenue decrease of $0.3 million or 8% compared to the six months ended February 29, 2020 was primarily due to lower revenue from DILIsym consulting services. Cost of revenue increased slightly during the same periods. Gross margin decreased $0.3 million or 11%, primarily due to the change in revenue.

Lixoft

For the six months ended February 28, 2021, the revenue increase of $2.8 million compared to the six months ended February 29, 2020 was due to the purchase of Lixoft on April 1, 2020. Software sales of Monolix Suite generated 96% of total revenue and 4% was generated from consulting services. Cost of revenue increased $0.4 million, and gross margin was $2.5 million due to the purchase of Lixoft on April 1, 2020.

Liquidity and Capital Resources

Historically, liquidity is provided by available cash and cash equivalents, cash generated from operations and access to capital markets.

In August 2020, we closed an underwritten public offering of 2,090,909 shares of our common stock to the public at $55.00 per share, which included the full exercise of the underwriters’ option to purchase 272,727 additional shares of common stock. The aggregate gross proceeds to us from this offering were approximately $115 million, before deducting underwriting discounts and commissions; net proceeds were approximately $107.7 million. The offering was made pursuant to our automatic shelf registration statement on Form S-3 filed with the SEC on July 9, 2020.

On March 31, 2020, we entered into a Stock Purchase and Contribution Agreement (the “Agreement”) with Lixoft. On April 1, 2020, we completed the acquisition of all outstanding equity interests of Lixoft pursuant to the terms of the Agreement, with Lixoft becoming our wholly owned subsidiary. We believe the combination of Simulations Plus and Lixoft provides substantial future potential based on the complementary strengths of each of the companies. Under the terms of the Agreement, we agreed to pay the former shareholders of Lixoft total consideration of up to $16.5 million, consisting of two-thirds cash and one-third newly issued, unregistered shares of our common stock. At closing, we paid the former shareholders of Lixoft a total of $10.8 million, comprised of cash in the amount of $9.5 million and the issuance of 111,682 shares of our common stock valued at $3.7 million, net of adjustments and a holdback for representations and warranties. In addition, we paid $3.5 million of excess working capital based on the March 31, 2020 financial statements of Lixoft. In addition, the Agreement calls for earnout payments up to an additional $5.5 million, two-thirds cash and one-third newly issued, unregistered shares of our common stock based on a revenue growth formula each year for the two years subsequent to April 1, 2020. The former shareholders can earn up to $2 million the first year and $3.5 million in year two. See Note 12, Acquisition, to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for a further description of the Agreement.

Cash Flows

 

Operating Activities

Net cash provided by operating activities was $6.6$3.6 million for the sixthree months ended February 28,November 30, 2021. Our operating cash flows resulted primarily from our net income of $5.7$3.0 million, which was generated by cash received from our customers, offset by cash payments we made to third parties for their services and employee compensation. In addition, net cash outflow from changes in balances of operating assets and liabilities was $3.7$1.8 million, offset by non-cash charges of $4.6$2.4 million. The change in operating assets and liabilities was primarily a result of an increase in accounts receivable.

 

35

Net cash provided by operating activities was $3.8$5.3 million for the sixthree months ended February 29,November 30, 2020. Our operating cash flows resulted primarily from our net income of $4.2$2.5 million, which was generated by cash received from our customers, offset by cash payments we made to third parties for their services and employee compensation. In addition, net cash outflowinflow from changes in balance of operating assets and liabilities was $2.5$0.6 million, offset byand non-cash charges of $2.1were $2.2 million. The change in operating assets and liabilities was primarily a result of an increasea decrease in accounts receivable,prepaid incomes taxes and revenue in excess of billings and a decrease in deferred revenue,billings.

Investing Activities

Net cash provided by investing activities during the three months ended November 30, 2021 of approximately $2.0 million was primarily due to the proceeds from the sale of short-term investments of 16.1 million, partially offset by an increase in accounts payablethe purchase of short-term investments of $12.7 million and a decrease in prepaid income taxes.

Investing Activitiesthe purchase of computer software development costs of $838 thousand.

 

Cash used for investing activities during the sixthree months ended February 28, 2021November 30, 2020 of $11.9$25.9 million was primarily due to the purchase of short-term investments of $40.8 million, the costs associated with the development of computer software of $1.5 million$31.0 and the purchase of equipmentcomputer software development costs of $0.6 million,$728 thousand, partially offset by the proceeds from the sale of short-term investments of $31.0$6.0 million. Cash used for investing activities during the six months ended February 29, 2020 of $1.2 million was primarily due to costs associated with the development of computer software.

 

Financing Activities

 

For the sixthree months ended February 28,November 30, 2021, net cash used byin financing activities of $1.6 million,$837 thousand was primarily driven by the payment of dividendsdue to dividend payments totaling $2.4$1.2 million, partially offset by proceeds from the exercise of stock options totaling $0.8 million. $372 thousand.

Net cash used byfor financing activities for the comparable period in fiscal yearthree months ended November 30, 2020, of $1.8$1.0 million was primarily due to dividend payments totaling $2.1 million, partially offset by proceeds of $0.3 million from the exercise of stock options.$1.2 million.

 

Cash and Working Capital

 

CashAs of November 30, 2021, the Company had $41.7 million in cash and cash equivalents were $42.4and $82.7 million as of February 28, 2021 compared to $49.2 million as of August 31, 2020.in short-term investments.

We have achieved continuous positive operating cash flow over the last twelve fiscal years.

 

At February 28,November 30, 2021, we had working capital of $129.0$130.3 million, a ratio of current assets to current liabilities of 20.714.6 and a ratio of debt to equity of 0.1. At August 31, 2020,2021, we had working capital of $123.6$127.7 million, a ratio of current assets to current liabilities of 23.412.0 and a ratio of debt to equity of 0.1.

 

Based upon

28

Contractual Obligations

The following table provides aggregate information regarding our current operating plans,contractual obligations as of November 30, 2021:

(in thousands) Payments due by period 
Contractual obligations: Total  1 year  2–3
years
  4–5
years
  More than
5 years
 
    
Operating lease obligations $1,224  $373  $618  $233  $ 
Contracts payable  4,671   4,671          
Total $5,895  $5,044  $618  $233  $ 

Known Trends of Uncertainties

Although we have not seen any significant reduction in total revenue to date, we did see a reduction in PKPD services during the year ended August 31, 2021, primarily resulting from project disruptions due to customer delays, holds, and drug development program cancellations. We have also seen some consolidation in the pharmaceutical industry during economic downturns although these consolidations have not had a negative effect on our total revenue from that industry. Should consolidations and downsizing in the industry continue to occur, those events could adversely impact our revenue and earnings going forward.

The world has been affected by the COVID-19 pandemic. Although there has not been a substantial impact on our sales revenue to date, until the pandemic has passed, there remains uncertainty as to the effect on our business in both the short and long term.

We believe that the need for improved productivity in the research and development activities directed toward developing new medicines will continue to result in increasing adoption of simulation and modeling tools such as those we produce. New product developments in the pharmaceutical business segments could result in increased revenue and earnings if they are accepted by our existing cash and cash equivalents, together with anticipated funds from operations,markets; however, there can be no assurances that new products will be sufficientresult in significant improvements to meetrevenue or earnings. For competitive reasons, we do not disclose all of our anticipated cash needs for working capital and capital expenditures for the foreseeable future. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect.new product development activities.

 

Our continued quest for acquisitions could result in a significant change to revenue and earnings if one or more such acquisitions are completed.

The potential for growth in new markets (e.g., healthcare) is uncertain. We will continue to explore these opportunities until such time as we either generate sales or determine that resources would be more efficiently used elsewhere.

Critical Accounting Estimates

 

Our condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. On an ongoing basis, management evaluates its estimates and judgments, including those related to recoverability and useful lives of long-lived assets, stock compensation, valuation of derivative instruments, allowances, contingent consideration, contingent value rights, fixed payment arrangements and going concern. Management bases its estimates and judgments on historical experience and on various other factors, including the COVID-19 pandemic, that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The methods, estimates, and judgments used by us in applying these critical accounting policies have a significant impact on the results we report in our condensed consolidated financial statements. Our significant accounting policies and estimates are included in our Annual Report on Form 10-K for the fiscal year ended August 31, 2020,2021, filed with the SEC on November 16, 2020.October 27, 2021.

36

 

Information regarding our significant accounting policies and estimates can also be found in Note 2, Significant Accounting Policies, to our condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

29

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

There has been no material change in our exposure to market risk from that described in Item 7A of our Annual Report on Form 10-K for the year ended August 31, 2020.2021.

 

Item 4. Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of February 28,November 30, 2021. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well-designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, management concluded as of February 28,November 30, 2021 that our disclosure controls and procedures were effective.

 

Changes in Internal Controls over Financial Reporting

 

No change in our internal controls over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act) occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

  

 

 

 3730 

 

 

PART II. OTHER INFORMATION

 

Item 1.Legal Proceedings

 

For a description of our material pending legal proceedings, please see Note 7, Commitments and Contingencies, to our condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

 

Item 1A.Risk Factors

 

Please carefully consider the information set forth in this Quarterly Report on Form 10-Q and the risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended August 31, 2020,2021, which could materially affect our business, financial condition, or future results. The risks described in our Annual Report on Form 10-K, as well as other risks and uncertainties, could materially and adversely affect our business, results of operations, and financial condition, which in turn could materially and adversely affect the trading price of shares of our Common Stock.common stock. Additional risks not currently known or currently material to us may also harm our business.

 

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3.Defaults Upon Senior Securities

 

None.

 

Item 4.Mine Safety Disclosures

 

Not applicable.

 

Item 5.Other Information

 

None.

 

31

Item 6.Exhibits

Item 6. Exhibits

 

EXHIBIT NUMBER DESCRIPTION
10.1 (1)2.1(3)^Agreement and Plan of Merger, dated July 23, 2014, by and among the Company, Cognigen Corporation and the other parties thereto
2.2(5)^Share Purchase and Contribution Agreement, dated March 31, 2020
3.1(2)Articles of Incorporation of the Company
3.2(2)Amended and Restated Bylaws of the Company
3.3(4)Certificate of Amendment to the Amended and Restated Bylaws of Simulations Plus, Inc.
4.1(1) Form of Common Stock Certificate
4.2(1)Share Exchange Agreement
4.3(6)Third Amendment to Lease,Revolving Line of Credit Note, dated as of December 28, 2020
10.2*†Separation Agreement, dated December 1,March 31, 2020, by and between the Company, as borrower, and John KneiselWells Fargo Bank, National Association, as lender
4.4(6)Credit Agreement, dated as of March 31, 2020, by and between the Company, as borrower, and Wells Fargo Bank, National Association, as lender
10.1(7)†First Amendment to Employment Agreement, by and between Simulations Plus, Inc. and Shawn O’Connor, dated November 19, 2021
31.1* Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
31.2* Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1* Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**2002**
101.INS* Inline XBRL Instance Document.
101.SCH* Inline XBRL Taxonomy Extension Schema Document.
101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104* Cover Page Interactive Data File – the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

________________________

 

^Schedules and exhibits omitted pursuant to Item 601(b)(2) of Registration S-K. The registrant agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request.
*Filed herewith
(1)Incorporated by reference to the Company’s Form 8-K filed with the SEC on January 4, 2021.
Those exhibits marked with a (†) refer to management contracts or compensatory plans or arrangements.
(1)Incorporated by reference to the Company’s Registration Statement on Form SB-2 (Registration No. 333-6680) filed on March 25, 1997.
(2)Incorporated by reference to an exhibit to the Company’s Form 10-K for the fiscal year ended August 31, 2010.
(3)Incorporated by reference to an exhibit to the Company’s Form 8-K/A filed November 18, 2014.
(4)Incorporated by reference to Appendix A to the Company’s Definitive Schedule 14A filed December 31, 2018.
(5)Incorporated by reference to an exhibit to the Company’s Form 8-K filed April 2, 2020.
(6)Incorporated by reference to an exhibit to the Company’s Form 8-K filed April 3, 2020.
(7)Incorporated by reference to the Company’s Form 8-K filed with the SEC on November 19, 2021.

 

 

 3832 

 

 

SIGNATURE

 

In accordance with Section 13 or 15 (d) of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lancaster, State of California, on April 14, 2021.January 7, 2022.

 

  Simulations Plus, Inc.
   
   
Date:April 14, 2021January 7, 2022By: /s/ Will Frederick      
  Will Frederick

  Chief Financial Officer

 

 

 

33

 

 

 

 

39